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ABSTRACT 
The glycine riboswitch is a structured RNA found upstream of genes in mRNA 
transcripts in many bacteria, functioning as a biofeedback gene regulator. Upon binding glycine, 
a complete RNA transcript including gene sequences is transcribed, effectively turning on gene 
expression. In  an  effort  to  understand  the  intricacies  of  its  functioning,  many mutants  of  
the riboswitch were made and characterized during Ph. D. work, resulting in discovery of a P0 
duplex/kink-turn motif involving a few nucleotides upstream of the established glycine riboswitch 
sequence which changed its ligand binding characteristics (Chapter 1). Previously, the two 
aptamers of the riboswitch were thought to cooperatively bind glycine, but with the inclusion of 
this leader sequence which forms a kink turn motif with the linker between the two aptamers, 
glycine binding in one aptamer no longer requires glycine binding in the other. Furthermore, the 
Kd from three species tested are now a similar, lower value of about 5 µM, indicating authenticity 
of this new consensus sequence. Glycine binding and interaptamer interaction both enhanced 
one another in trans aptamer assays. Another discovery from this was a shortened construct 
including all of aptamer II but only part of aptamer I in which a few specific nucleotides 
prevented glycine binding in aptamer II (Chapter 2). This may provide insight into the nature of 
interaptamer interactions in the full switch; addition of an oligonucleotide complimentary to these 
nucleotides restored glycine binding ability to aptamer II. With future development, this could 
also be a useful molecular biology tool, using two signals, glycine and an oligonucleotide, to 
allow gene expression. 
To precisely understand how any macromolecule functions, a 3D structure, obtainable 
by x-ray crystallography, is vital. A new technique to accomplish that for RNA, precedented in 
the protein world, is Fab chaperoned crystallography, which has advantages compared to RNA 
alone. A phage displayed library of Fabs with reduced codon diversity designed for RNA was 
created, the YSGR Min library (Chapter 3). Its Fabs had specificities and affinities equal to or 
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greater than previous libraries which were originally created for phage displayed selection 
against proteins. Fab chaperoned RNA crystallography is currently in progress for the glycine 
riboswitch; the best resolution thus far is 5.3 Å (Chapter 4). In addition to providing molecular 
insight into its gene regulation mechanism, a structure of the glycine riboswitch could be applied 
for use in structure based drug design of novel antibiotics targeting the riboswitch to disrupt 
important downstream carbon cycle genes in pathogenic bacteria. 
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CHAPTER 1  AN ENERGETICALLY BENEFICIAL LEADER-LINKER INTERACTION 
ABOLISHES LIGAND COOPERATIVITY IN GLYCINE RIBOSWITCHES 
1.1 Introduction 
 
Riboswitches are cis-acting mRNA elements that regulate gene expression by direct 
binding to small molecule metabolites (1). Upon binding of the biologically important 
metabolites, riboswitches undergo conformational changes which may affect the structure of the 
associated expression platforms and control gene expression through transcriptional 
termination, translational initiation, or alternative splicing. Many riboswitches have been 
computationally discovered and experimentally verified (1, 2). Most of the currently reported 24 
classes of riboswitches are found in the 5’ UTRs of bacterial genes, though TPP riboswitches 
are also present in plants and fungi (3, 4). They vary widely in their structures and functional 
mechanisms, discriminatively sensing a plethora of metabolites (1, 2, 5). 
Glycine riboswitches are among the earliest discovered riboswitches (6). Using BLASTN 
searches followed by iterative secondary structure refinement and extension with the 
SEQUENCESNIFFER program, Breaker and coworkers identified a gcvT motif that resides 
upstream of bacterial genes expressing enzymes involved in the metabolism of glycine (6, 7). 
The gcvT motif, termed the glycine riboswitch, forms an on-switch when bound to glycine, 
controlling the expression of enzymes that catalyze the initial reactions for the use of glycine as 
an energy source. These enzymes are components of the glycine cleavage system which 
breaks down glycine and produces carbon dioxide, ammonia, and 5-10-
methylenetetrahydrofolate in the presence of tetrahydrofolate (8). 5-10-
methylenetetrahydrofolate serves as sources of the methyl groups for methionine and 2’-
deoxythymidine biosynthesis (9). In addition, 5-10-methylenetetrahydrofolate can also serve as 
the substrate in the reversible conversion of glycine to serine. Combined together, glycine and 
serine account for up to 15% of carbon assimilated by E. coli growing on glucose (10). Besides 
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their direct roles in protein synthesis, glycine and serine serve as precursors for purines, heme 
groups, cysteine, phosphatidylserine, enterochelin and tryptophan (11, 12). Thus, the glycine 
riboswitch self-regulates by biofeedback an important metabolite that serves as precursor to one 
of the main biosynthetic trunks in bacteria (12). 
Interestingly, glycine riboswitches contain two tandem glycine-sensing domains and 
purportedly employ, uniquely, ligand binding cooperativity. The most biochemically 
characterized construct, Vibrio cholerae (VC) glycine riboswitch was reported to bind glycine 
with a Hill coefficient of 1.5 to 1.6 (6, 13, 14), the largest amongst all reported glycine 
riboswitches. Deleterious mutations in each aptamer of the VC glycine riboswitch also greatly 
reduced the glycine binding affinity in the other aptamer, providing direct evidence of the ligand 
binding cooperativity of the tandem riboswitch (6, 14). As the first example of naturally occurring 
RNA elements reported to bind small organic molecules cooperatively (6, 15), glycine 
riboswitches have inspired many biochemical and biophysical studies, including nucleotide 
analog interference mapping (NAIM) to investigate the chemical basis of the cooperativity (13) 
and small-angle X-ray scattering (SAXS) to dissect the roles of metal ions and ligand binding in 
structural transitions (16, 17). Recent efforts have resulted in the proposal of the asymmetrical 
model of glycine binding cooperativity (14) as well as crystal structures of the single aptamer 
VCII with an extended P1 helix (18) and the tandem glycine riboswitch from Fusobacterium 
nucleatum (19). 
In working with the tandem VC glycine riboswitch, we have found our minimal construct 
exhibited a distinctive protection pattern in the linker region compared to literature results. This 
led to the discovery of a surprising leader-linker interaction involving nucleotides upstream of 
the reported consensus glycine riboswitch sequences. We have defined the energetic benefit of 
the leader-linker interaction through in-line probing of the tandem riboswitches and further 
characterized its effect on glycine binding and inter-aptamer interaction using biochemical 
assays with two aptamers in trans. Our mutational analysis surprisingly showed inter-aptamer 
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inhibition does not exist in the full-length VC glycine riboswitch. Together, our data suggest 
glycine binding and inter-aptamer interaction synergize to fold the global structure of the glycine 
riboswitch in which its two aptamers do not bind glycine cooperatively.  
1.2 Results 
 
1.2.1 Discovery of the leader-linker interaction 
 
 As RNA tertiary structures are generally more flexible than proteins, to reduce terminal 
entropy and increase crystallizability of RNAs, crystallographers generally remove the single 
stranded flanking regions from their RNA constructs. In an attempt to crystallize the VC tandem 
glycine riboswitch, we have constructed the minimal sequence VCI-IIs (nts 7 to 225, Fig. 1.1A). 
The overall glycine binding characteristics of VCI-IIs (Kd = 47 ± 14 µM, Table 1.1, Fig. 1.2) are 
very similar to VCI-II (nts 1 to 225, Kd = 59 ± 12 µM, Table 1.1). In the linker region (nts 135 to 
137), VCI-IIs remained unstructured independent of glycine concentration (Fig. 1.2) while VCI-II 
exhibited local structure flexibility with increasing glycine concentration (6). This suggested that 
its 5’ leader sequence may influence the structure of the linker region. One simple scenario is 
direct duplex formation between the leader and the linker region, which proved correct upon 
sequence retrieval from the NCBI database and manual comparison of the leader with the linker 
sequences. Thus, a leader-linker duplex (termed P0) beyond the published consensus glycine 
sequence was unearthed. Supported by Mfold (20), the P0 helix contains 3-7 base pairs and is 
96% conserved (53 out of 55) in the tandem glycine riboswitch sequences reported by Breaker 
and coworkers (6). In addition, the P0 helix is present in 91% of the 22 tandem glycine 
riboswitch seed sequences in Rfam (21).  Further analysis showed that in 40% of these glycine 
riboswitches, P0 helices are connected to P1 through simple internal loops/bulges (Fig. 1.3). In 
the rest (over 50%) of the glycine riboswitch sequences (Fig. 1.1B), however, P0 helices are 
connected to P1 through kink-turn motifs (22-25). Three characteristics show that these motifs 
fit the pattern of the consensus kink-turns derived from the ribosome kink-turns: 1) The C stems 
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most often end with two C-G/G-C pairs; 2) The internal loop follows the RNN(N) consensus rule; 
3) the NC stems usually start with two sheared G-A/A-G base pairs. Interestingly, the canonical 
base pair adjacent to the internal loop (-1b/-1n pair) has a strong preference for G-C, just the 
opposite to the C-G base pair preference in the ribosome, indicating a possible deviation from 
the consensus kink-turn motif, as the G-C pair may not support the type I A-minor interaction as 
well as C-G (22).   
Table 1.1 Binding affinities and Hill coefficient values of glycine riboswitches and mutantsa 
RNA Kd (µM) Hill coefficient 
(n) 
Description of the constructs 
VCI-II 59 ± 12 
64 ± 17b,c 
1.3 ± 0.2 nts 1 to 225 
VCI-IIs 47 ± 14 1.1 ± 0.2 nts 7 to 225 
VCLD 5.0 ± 4.0 0.6 ± 0.2 nts -7 to 225 
VCI-IILN 15 ± 3 1.4 ± 0.2 nts 1 to 225, GGA136-138CCC 
VCLDLN 61 ± 11 1.3 ± 0.2 nts -7 to 225, GGA136-138CCC 
VCII133d (2.0 ± 0.1)  
103 
≤ 1 nts 133 to 225 
VCII133 (+VCI132)d 191 ± 44 ≤ 1 VCII133 with 15 µM VCI132 
VCII133 (+VCI132LD)d 7.4 ± 1.0 ≤ 1 VCII133 with 15 µM VCI132LD 
VCI132 (+VCII133)e (7.4 ± 1.0)  
103 
≤ 1 nts 1 to 132, with 15 µM VCII133 
VCI132LD (+VCII133)e 190 ± 41 ≤ 1 nts -7 to 132, with 15 µM 
VCII133 
VCI-IIG17Cd (1.1 ± 0.1)  
103 
≤ 1 nts 1 to 225, G17C 
VCI-IIG146C (1.9 ± 0.3)  
103 
≤ 1 nts 1 to 225, G146C 
VCLDG17Cd 2.8 ± 0.4 ≤ 1 nts -7 to 225, G17C 
VCLDG146Ce 12 ± 2 ≤ 1 nts -7 to 225, G146C 
FNI-II 14 ± 6 
8.6 ± 0.4b 
1.1 ± 0.1 
0.9 ± 0.1 
nts 1 to 158 
FNLD 3.1 ± 2.5 0.7 ± 0.2 nts -11 to 158 
BSI-II 311 ± 158c  nts 13 to 202 
BSLD 3.6 ± 3.4 0.8 ± 0.2 nts 1 to 202 
aDetermined by in-line probing assay unless indicated otherwise. Binding affinities were 
calculated as average Kd values obtained from the individual glycine perturbed regions in at 
least two independent trials with curve fit coefficients better than 0.98. Hill coefficients were 
calculated in a similar way but only from those with curve fit coefficients better than 0.99. 
bDetermined by hydroxyl radical footprinting.  
cAverage Hill coefficient is not determined as the curve fit coefficients are less than 0.99. 
dBinding parameters were calculated for aptamer II regions. 
eBinding parameters were calculated for aptamer I regions. 
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Figure 1.1 VC glycine riboswitch secondary structure and leader linker kink turn sequence 
alignment. 
 
(A) Secondary structure of the full-length VC glycine riboswitch. r2-r7 and *a-*b indicate the 
representative glycine induced perturbation regions in the in-line probing assay and the hydroxyl 
radical footprinting assay of VCI-II, respectively; the corresponding nucleotides are circled. “I” 
and “II” refer to aptamer I and aptamer II, respectively. Green, yellow, cyan, purple, and grey 
regions indicate C stem (P0 helix), internal loop, NC stem, P1 helix of aptamer I, and P1 helix of 
aptamer II, respectively. The kink-turn motif is shown in a black box. Red nucleotides indicate 
previously defined linker sequence. (B) Alignment of the kink-turn motifs formed between leader 
and linker regions in 31 of 55 tandem glycine riboswitch sequences reported by Breaker and 
coworkers (Mandal et al. 2004). Abbreviations of the names of the organisms are taken from the 
same article.  
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Figure 1.2 Representative in-line probing gel image of VCIIIs.  
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. r2-r7 indicate regions defined in Table 1.2. 
  
NR OH T1
Glycine
r7
r6
r5
r4
r3
r2
G66
G137
G118
G96
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Atu: ...AGCGUCGCAUCAUCGUUGG.........CCAGCGAUGACGACGGAA-CUCUG... 
Bja: ...UGUAUCGUACGGCCACGUCGG.....CCG-CGUGGCUUUGACAGC--AUCUG... 
Bme: .....UCUUGCACUGUCUGUUUGCGG....CCGCAGGCGGGUAAGACAA-CUCUG... 
Brs: ....UCUUGCACUGUCUGUUUGCGG.....CCGCAGGCGGGUAAGACAA-CUCUG... 
Ccr: ....AGCCCUCGACCCUCGCGG.......CCGCGCGGGUUUAGGAA----CGCUG... 
Ccr: ...UCCUCAAAGGCCUCUCGCGG......CCGCGCGAGACGUUGAA----CGCUG... 
Mlo: ...UCGAGUCCUACCUGUUUGCGG...CCGUAGACGGGAAAGACA-----CUCUG... 
Mlo: ...GGUGUUCAAAGGCUGGA-CGG......CCGCACC-GCCGAACG----AUCUG... 
Sme: ....UGGAUUCGACCUCGUUGG......CCAGCAAGGUGCCGGUAGGA--CUCUG... 
Bbr: ...UCCACCAACGUGCAGUUCGG.........CCGACCUGCUGGAAC---AUCUG... 
Bbr: ...GCGCUGUCACGCAUGUCGCGG.CCGCGAC-UGCAUCGAGUAGCGC..CUCUG... 
Bpa: .....UUCCACCAACGUGCAGUUCGG......CCGACCUGCUGGAAC---AUCUG... 
Bpa: ...GCGCUGUCACGCAUGUCGCGG.CCGCGAC-UGCAUCGAGUAGCGC..CUCUG... 
Bpe: ...GCGCUGUCACGCAUGUCGCGG.CCGCGAC-UGCAUCGAGUAGCGC..CUCUG... 
Cvi: ...CUAAUAUUCCGGUUCUGCGG......CCGCAGCGCCGUAUAGAA...GAUUG... 
Cvi: ...AUC-GCCGGGUCAUACAG.........CUGUAUCAUCGGGCCGG...AUCUG... 
Neu: ....GCUGAUAUUUCAUCCAGGCAG.......CUGCUUGUGAUUGGCAA--UCUG... 
Rso: ...UCCGGCCAUCCAUCCGG..........CCGGGUGGAUCGGCUGGG..CUCUG... 
Xax: .......UAU...ACACGG-UGG.........CCAUCCGCAGUACAAC--CUCUG... 
Xfa: .....AUGGGGUGCGUC...............GGCGCAAGGUUCGU....CUGUG... 
Mbo: ....GCAUCGCUCUAGUGCGG.......CCGCGCGAGACUACGAUGC---CUCUG... 
Mtu: ....GCAUCGCUCUAGUGCGG.....CCGCGC--GAGACUACGAUGC---CUCUG... 
 
Figure 1.3 Leader linker sequence alignment for loops. 
 
Alignment of leader-linker P0 duplex connected to P1 duplex with simple internal loops in 22 of 
55 tandem glycine riboswitch sequences reported by Breaker and coworkers (Mandal et al. 
2004). Abbreviations of the names of the organisms are taken from the same article. Green, 
yellow, purple, and grey regions indicate P0 duplex, internal loop, P1 helix of aptamer I, and P1 
helix of aptamer II, respectively. 
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1.2.2 The global structures of the full-length glycine riboswitches are similar to those of 
the truncated constructs 
 
To evaluate the global structures of the full-length glycine riboswitches, we have 
constructed both full-length and truncated versions of the glycine riboswitches from three 
organisms: Vibrio cholerae [VCLD (nts -7 to 225) and VCI-II], Fusobacterium nucleatum [FNLD 
(nts -11 to 158) and FNI-II (nts 1 to 158)] and Bacillus subtilis [BSLD (nts 1 to 202) and BSI-II 
(nts 13 to 202)]. These RNA sequences are downstream of the transcription start sites predicted 
by Prokaryotic Promoter Analysis Using Sequence Alignment Kernel software (26). 
Interestingly, the Bacillus subtilis glycine riboswitch previously reported (6) contains the leader 
sequence although the leader-linker interaction was not recognized. In-line probing assays map 
the local structure changes by measuring the flexibility of the phosphodiester bond to achieve 
in-line geometry for non-enzymatic cleavage through internal transphosphorylation (27, 28). 
Under standard in-line probing conditions (50 mM Tris-HCl, pH 8.3, 20 mM MgCl2, 100 mM KCl, 
25 oC) with saturating glycine concentrations, the full-length glycine riboswitches exhibit the 
same protection patterns as the truncated ones outside of the linker region in all three VC, FN 
and BS glycine riboswitches (Fig. 1.4A, 1.5, 1.6, 1.7). To compare the regions directly, we 
calculated the relative band intensities of the major cleavage bands and known glycine-
perturbed regions. Results showed that these bands have similar relative intensities within any 
given construct in the in-line probing assay of glycine riboswitches with or without leader 
sequences (Table 1.2). In the linker region, the full-length glycine riboswitches are protected 
from spontaneous cleavage while the truncated glycine riboswitches show cleavage bands, 
consistent with a leader-linker interaction. Therefore, in-line probing assays showed that except 
for the linker regions, the full-length glycine riboswitch folds into the same structure as the 
truncated constructs at high magnesium and glycine concentrations. 
 
  
10 
 
Table 1.2 Comparison of glycine riboswitches’ protection patterns with and without the leadera 
Regions VCI-IIb VCLDb FNI-IIc FNLDc BSI-IId BSLDd 
r7 0.14 ± 0.01 0.13 ± 0.05 0.10 ± 0.03 0.10 ± 0.04 0.78 ± 0.13 0.42 ± 0.03 
r6 0.10 ± 0.02 0.13 ± 0.06 0.07 ± 0.01 0.08 ± 0.03 0.29 ± 0.02 0.11 ± 0.02 
r5 0.12 ± 0.01 0.12 ± 0.07 0.04 ± 0.01 0.09 ± 0.08 0.21 ± 0.01 0.16 ± 0.01 
r4e 1.90 ± 0.50 0.11 ± 0.07 11.4 ± 6.1 0.11 ± 0.05 2.2 ± 0.3 0.20 ± 0.02 
r3 0.29 ± 0.09 0.16 ± 0.06 0.03 ± 0.01 0.02 ± 0.02 0.64 ± 0.21f 0.13 ± 0.02f 
r2 0.18 ± 0.02 0.12 ± 0.02 0.18 ± 0.02 0.08 ± 0.07 0.23 ± 0.07f 0.05 ± 0.01f 
ref1 1 1 1 1 1 1 
ref2 0.72 ± 0.09 0.65 ± 0.06 5.1 ± 1.6 4.6 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 
aDetermined as relative intensities of each region normalized to non-variable band ref1 at 20 
mM magnesium and 3.16 mM glycine in in-line probing assay. Data are averaged from at least 
two independent trials. 
bFor VCI-II and VCLD, regions are as the following: C177-A178 (r7), G170-A172 (r6), G146 (r5), 
G136-G137 (r4), A121-G123 (r3), U74 (r2), U156-U161 (ref1), and U94 (ref2), which are 
indicated in Figure 1.1. 
cFor FNI-II and FNLD, regions are as the following: C117-A119 (r7), G110-A112 (r6), G85 (r5), 
G72-G76 (r4), G61 (r3), U46 (r2), C90 (ref1), and U96-A100 (ref2).  
dFor BSI-II and BSLD, regions are as the following: A158-G160 (r7), A151-A153 (r6), G121 (r5), 
G109-A115 (r4), A93-A96 (r3), U83 (r2), G136-U138 (ref1), and U126 (ref2). 
eData in r4, the linker regions, are shown in bold to show that the truncated glycine riboswitches 
are cleaved much more than the full-length constructs.   
fIn some regions, BSI-II showed 5 fold more cleavage than BSLD, indicating BSI-II may be more 
flexible and dynamic. 
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Figure 1.4. Semi-log Kd plots comparing in-line probing of full-length and truncated glycine 
riboswitches. 
  
(A) Representative in-line probing gel image of BSLD. NR, T1, and OH represent no reaction, 
partial digestion with RNase T1, and partial digestion with alkali, respectively. r2-r7 indicate 
regions defined in Table 1.2. (B) Representative semi-log plots of the normalized fraction of 
RNA bound versus glycine concentration. Shown from top to bottom: VCLD/VCI-II (r3); 
FNLD/FNI-II (r6); BSLD/BSI-II (r6). 
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Figure 1.5 In-line probing gel images of VCLD (A) and VCI-II (B).  
 
T1 and OH represent partial digestion with RNase T1 and partial digestion with alkali, 
respectively. r2-r7 indicate regions defined in Table 1.2. 
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Figure 1.6 In-line probing gel images of FNLD (A) and FNI-II (B).  
 
NR represents no reaction. r2-r7 indicate regions defined in Table 1.2. 
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Figure 1.7 In-line probing gel images of BSLD (A) and BSI-II (B).  
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. r2-r7 indicate regions defined in Table 1.2. 
 
As in-line probing assays may detect structure formation with heavy focus on secondary 
structures, to compare tertiary structures of the glycine riboswitches, we employed hydroxyl 
radical footprinting (HRFP), one of the most frequently used methods for studying RNA folding 
(29-32). HRFP is sequence independent and measures the perturbation of solvent accessibility 
of local tertiary structures during conformational change by hydroxyl radical triggered RNA 
backbone cleavage. Similar to the in-line probing results, HRFP experiments showed that, at 
saturating glycine concentrations, the full-length glycine riboswitches exhibit the same protection 
r7
r6
r5
r4
r3
r2
NR T1 OH
Glycine
r7
r5
r4
r3
r2
GlycineA B
NR T1 OH
r6
15 
 
patterns as the truncated ones outside of the linker region in all three VC, FN and BS glycine 
riboswitches (Fig. 1.8, 1.9, 1.10).  
Combining in-line probing and HRFP experiments, results showed that full-length glycine 
riboswitches fold into the same global structure as the truncated version at saturating 
magnesium and glycine concentrations.  
 
 
Figure 1.8 Hydroxyl radical footprinting gel images of VCI-II (A) and VCLD (B).   
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. *a (nts 200-202), *b (nts 170-172), *c (around nt 146), *d (around nt 
123) and *e (around nt 82), as indicated in Figure 1.1, represent the glycine-induced protections 
in VCI-II, which correlate well with previous reports (Lipfert et al. J. Mol. Biol. 2007, 365, 1393; 
Erion and Strobel RNA 2011, 17, 74). 
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Figure 1.9 Hydroxyl radical footprinting gel images of FNI-II (A) and FNLD (B).   
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. *a (nts 134-136), *b (nts 117-119), *c (nts 110-112), *d (nts 85-86), and 
*e (nts 63-67) represent the glycine-induced protections in FNI-II. 
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Figure 1.10 Hydroxyl radical footprinting gel images of BSI-II (A) and BSLD (B). 
 
NR and T1 represent no reaction and partial digestion with RNase T1, respectively. X 
represents the lane below a damaged well without sample loading. *a (around G121), *b 
(around G97), *c (around C88), and *d (around G60) represent the glycine-induced protections 
in BSI-II. 
 
1.2.3 Energetic benefit of the leader-linker interaction 
 
Unexpected tertiary structures involving flanking sequences of functional RNAs have 
been reported before and are functionally beneficial. For instance, the loop/bulge interaction 
involving the 5’ flanking sequence of the hammerhead ribozyme increases the catalytic rate 
substantially (33, 34). To understand the functional benefit of the leader-linker interaction, we 
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obtained the ligand binding affinities of the full-length glycine riboswitches through in-line 
probing assays at standard conditions similar to that reported previously for glycine riboswitches 
(6, 13, 14) (Fig. 1.4, 1.5, 1.6, 1.7). In the linker regions, the full-length glycine riboswitches 
showed constant protection with or without glycine, suggesting the leader-linker interaction is 
formed independent of glycine. Other glycine-perturbed regions, including both aptamer I and 
aptamer II regions, showed similar glycine binding affinities for the full-length constructs within 
experimental error. The affinities calculated from all the major glycine-perturbed regions over at 
least two duplicated experiments were averaged together and tabulated in Table 1.1. Results 
showed that glycine binding affinities of the full-length constructs have been increased by 4.5 to 
86 fold compared to the truncated ones. This corresponds to a free energy benefit of 0.9-2.7 
kcal/mol under standard in-line probing conditions. Interestingly, all three full-length riboswitches 
showed similar glycine binding affinities with Kds of 5.0 ± 4.0 µM, 3.1 ± 2.5 µM, and 3.6 ± 3.4 µM 
for VCLD, FNLD and BSLD, respectively, while the truncated constructs showed much more 
varied glycine binding affinities. We have also obtained glycine binding affinities with HRFP, 
which gave similar values for VCI-II and FNI-II. However, we could not obtain any visible glycine 
perturbation for the full-length constructs using HRFP. At the corresponding regions where 
glycine induces protection in the truncated glycine riboswitches, full-length constructs exhibit 
protection with or without glycine, precluding visible perturbation. Typically, hydroxyl radical 
footprints are observed for the interior portion of closely packed helical segments for structured 
RNAs. We inspected the protected regions of FNI-II in the published crystal structure (19) in 
PyMol (www.pymol.org) and found these regions are mostly buried between the two aptamers. 
For instance, the sugar moieties (HRFP susceptible) of nts 63-67, nts 134-136 and nts 117-119 
are buried by the α-α’ inter-aptamer interaction; sugar moieties of nts 85-86 are partially buried 
by the β-β’ inter-aptamer interaction and the packing against flipped base A111 which is very 
important for the formation of the glycine binding pocket; nts 110-112 directly participate in the 
glycine binding pocket. The HRFP protection in these regions of FNLD in the absence of glycine 
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suggests that the full-length constructs promote the inter-aptamer interaction, form more 
compact and organized pockets for glycine binding, and render any possible further compaction 
by the glycine binding undetectable through HRFP experiments. 
1.2.4 Mutation in the linker region selectively reduces the ligand binding affinities of the 
full-length but not the truncated glycine riboswitches  
 
 The full-length glycine riboswitches exhibit significantly higher ligand binding affinities 
compared to the truncated ones. To link the energetic benefit directly to the leader-linker 
interaction, we focused on the VC glycine riboswitch, which was studied most extensively with 
biochemical analysis. Incorporating a GGA136-138CCC mutation to prevent the formation of the 
P0 helix, we prepared VCI-IILN and VCLDLN, the linker mutants in the truncated and full-length 
VC glycine riboswitches, respectively. Similar to the wild-type constructs, the linker mutants also 
showed similar glycine binding affinities in both aptamer I and aptamer II regions within 
experimental error. The glycine binding affinities were calculated as the average affinities of all 
the major regions over at least two duplicated experiments. Results showed that VCLDLN binds 
glycine with a Kd of 61 ± 11 µM (Fig. 1.11A; Table 1.1), very similar to that of VCI-II, 59 ± 12 µM, 
losing the entire energetic benefit (12 fold) of the leader-linker interaction observed in VCLD. 
This affinity loss could be potentially caused by a loss of an unidentified linker interaction with 
regions other than the 5’ leader. To control for this possibility, we obtained the glycine binding 
affinity of VCI-IILN. Unlike VCLDLN, the linker mutation in VCI-IILN did not reduce the glycine 
binding affinity compared to VCI-II, consistent with the model that leader-linker interaction 
contributes solely to the energetic benefits in VCLD. In fact, there is about 4-fold increase in the 
glycine binding affinity of VCI-IILN compared with VCI-II (Fig. 1.11B; Table 1.1). Both VCI-II and 
VCI-IILN contain three guanosines at the 5’ with two artificial guanosines added for improved 
transcription efficiency. Suggested by Mfold (20), this GGG sequence could potentially pair with 
CCC136-138 in VCI-IILN and form an imperfect kink-turn motif (only two nucleotides in the 
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internal loop). Thus, this 4-fold increase of glycine binding affinity of VCI-IILN versus VCI-II is 
also consistent with the functional role of the leader-linker interaction. 
Figure 1.11 Comparison of the ligand binding of the linker mutants with wild-type VC glycine 
riboswitches.  
 
(A) and (B) show the representative semi-log plots of the normalized fraction of RNA bound 
versus glycine concentration for r3 region (A121-G123) of VCLD with VCLDLN, and VCI-II with 
VCI-IILN, respectively. 
 
1.2.5 Leader-linker interaction greatly enhances the inter-aptamer interaction 
 
HRFP experiments showed that full-length glycine riboswitches promote the inter-
aptamer interaction and form more compact structures in the absence of glycine. To observe 
the effect of the leader-linker interaction on inter-aptamer complexation directly, we designed 
the individual aptamers of the VC glycine riboswitch and analyzed the inter-aptamer binding with 
native gel assays. We have prepared two different aptamer I constructs, with (VCI132LD, nts -7 
to 132) and without the 5’ leader (VCI132, nts 1 to 132), and one aptamer II construct with the 
entire linker region (VCII133, nts 133 to 225). This design prevents self-association of aptamer I 
through leader-linker interaction by placing the entire linker region on aptamer II and precludes 
inter-aptamer duplex formation in P1 regions by avoiding any overlapping bases between 
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aptamers, thereby allowing direct measurement of the possible enhancement of the inter-
aptamer complex formation through leader-linker interaction. We 5’ 32P labeled VCII133 and 
incubated it with unlabeled VCI132LD or VCI132 at concentrations ranging from 0 to ~100 µM 
under native conditions (10 mM MgCl2, 5 mM glycine). The mixture was then resolved via native 
gel based on a polyacrylamide coelectrophoresis (PACE) method (13, 35) with radiolabeled 
VCLD as a size marker (Fig. 1.12A). VCII133 showed small fractions of probable self-
complexation independent of aptamer I concentration (similar phenomenon noted previously in 
different experiments). With increasing amounts of VCI132, a new complex with increasing 
intensity was formed and co-migrated with VCLD, suggesting that it is a reconstituted complex 
between VCII133 and VCI132. The intensity of the reconstituted complex reached 16% with 25 
µM VCI132 and dropped abruptly to 9% at ~100 µM VCI132, presumably due to possible 
dimerization of VCI132 at such a high concentration. With increasing amounts of VCI132LD, 
similar complexes with increasing intensity were formed and co-migrated with VCLD. 
Interestingly, on a well resolved PACE gel, we observed two closely migrating bands for the 
VCI132LD/VCII133 complex. We reasoned that without covalent linkage between two aptamers, 
the kink-turn motif formed between leader and linker may assume two different conformations or 
dock into the rest of the glycine riboswitch in two different geometries. The reconstituted 
complexes of VCI132LD/VCII133 were formed more readily and reached 52% with 50 µM 
VCI132LD before dropping abruptly to 44% at 100 µM VCI132LD similar to that observed for 
VCI132. Plotting complex formation vs. aptamer I concentration (excluding the data at ~100 µM 
aptamer I) gives Kd values of 0.66 ± 0.16 µM and  6.3 µM (Fig. 1.12B)  for VCI132LD and 
VCI132, respectively (the Kd for VCI132 is estimated for lack of plateau at high aptamer I 
concentration). This shows that the leader-linker interaction enhanced the inter-aptamer 
interaction by  10 fold under native conditions, consistent with the energetic benefit obtained 
previously. 
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Figure 1.12 Native gel and graph of covalently disconnected aptamers I and II to reconstitute 
the switch from these trans aptamers by interaptamer interaction. 
 
(A) Native gel image of 32P labeled VCII133 titrated with aptamer I constructs in 10 mM MgCl2 
and 5 mM glycine. Lane 1, 32P labeled VCLD; lane 2, 32P labeled VCII133; lane 3-8, 32P labeled 
VCII133 with 0.2 to 97 µM of VCI132; lane 9-21, 32P labeled VCII133 with 0.2 to 100 µM of 
VCI132LD. (B) Semi-log plots of unnormalized fraction of VCII133 bound versus aptamer I 
concentration. 
 
1.2.6 Glycine binding properties of individual aptamers 
 
 To better dissect the roles of inter-aptamer interaction and glycine binding on native 
glycine riboswitch folding in cis or in trans, we set out to analyze the glycine binding properties 
of the individual aptamers with in-line probing experiments. Neither VCI132 nor VCI132LD 
showed glycine-dependent modulation (data not shown), consistent with previous reports that 
aptamer I may not be capable of independent glycine binding, at least within the limits of the in-
line probing method (14). In addition to the aforementioned two and two other aptamer I 
constructs reported previously (14),VCI139 (nts 1 to 139) and VCI150 (nts 1 to 150), we have 
also tested VCI145 (nts 1 to 145), VCI145LD (nts -7 to 145), VCI151 (nts 1 to 151), VCI151LD 
(nts -7 to 151), VCI166 (nts 1 to 166), VCI177 (nts 1 to 177) and VCI189 (nts 1 to 189), covering 
half of aptamer II. In-line probing experiments showed that none of these constructs bind glycine 
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(data not shown), not even with the 5’ leader on some of the constructs (VCI145LD and 
VCI151LD). These experiments definitively showed that aptamer I does not bind glycine 
independently. Interestingly, aptamer II construct VCII133 does not bind glycine properly either 
(Kd of 2.0 ± 0.1 mM; Table 1.1), although VCII122 (nts 122 to 225) binds glycine with a Kd of 4.4 
± 1.9 µM, consistent with previous reports (6, 14). Further analysis showed that other VC 
aptamer II constructs shorter than VCII122 such as VCII127 (nts 127 to 225) and VCII130 (nts 
130 to 225) also do not bind glycine (data not shown). An aptamer II construct with blunt end P1 
helix VCII140m1 (nts 140 to 225, with CC140-141GG and GG224-225CC mutation) binds 
glycine with a Kd of 1.4 ± 0.2 mM, 300 fold weaker than VCII122, although it has been reported 
that a VC aptamer II construct with a wobble pair mutation and extended P1 helix binds glycine 
with a Kd of 3.5 ± 1.5 µM at 20 mM MgCl2 analyzed by ITC experiment (18). These results 
strongly suggest that wild-type VC aptamer II sequences also need part of aptamer I structural 
elements to bind glycine properly. VCII122 contains 11 nucleotides from aptamer I, and it may 
happen to mimic the inter-aptamer interaction needed for aptamer II to bind glycine properly or 
assume an alternative conformation that allowed proper glycine binding. Further evidence 
supporting that individual aptamers need structural elements on the other aptamer comes from 
the FN glycine riboswitch. The corresponding constructs of VCI145, VCI151, and VCII122 on 
FN glycine riboswitch are FNI84 (nts 1 to 84), FNI90 (nts 1 to 90), and FNII61 (nts 61 to 158), 
none of which bind glycine in the in-line probing experiments (data not shown). 
1.2.7 Leader-linker interaction greatly enhances the glycine binding affinities of the 
individual aptamers 
 
Via native gel assays, we have also tried to analyze the complex formation between 
aptamer I and aptamer II without glycine. However, no complex was visible without glycine 
added in the gel when VCII133 was incubated with either VCI132 or VCI132LD (data not 
shown). The previous section showed that without proper inter-aptamer interaction, an individual 
aptamer does not bind glycine properly. These two observations suggest that glycine binding 
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and inter-aptamer interaction (assisted by leader-linker interaction) have to function 
synergistically in global glycine riboswitch folding. The PACE gel results showed that saturating 
glycine helps aptamers interact with each other in trans and form the inter-aptamer complex. 
We then sought to investigate whether a saturating concentration of an individual aptamer will 
enhance glycine binding on the other aptamer and what role the leader-linker interaction might 
play. We carried out the in-line probing experiment using radiolabeled VCII133 incubated with 
15 µM VCI132 in the presence of a range of glycine concentrations. Results showed that 
VCI132 greatly enhances the glycine binding of VCII133 from 2 mM to a Kd of 191 ± 44 µM (Fig. 
1.13A; Table 1.1). When 15 µM VCI132LD was added to the in-line probing assay, VCII133 
showed glycine binding with a Kd of 7.4 ± 1.0 µM (Fig. 1.13A; Table 1.1), enhanced 26 fold 
further from that with VCI132, restoring the glycine affinity almost completely to that of the full-
length tandem riboswitch. This enhancement is slightly better than the ~12 fold enhancement of 
VCLD versus VCI-II, suggesting that the leader-linker interaction benefits more in trans, which is 
consistent with its role in holding the two aptamers together. We also carried out the in-line 
probing experiment using radiolabeled VCI132 incubated with 15 µM VCII133 in the presence of 
a range of glycine concentrations. Results showed that VCII133 rescues the glycine binding of 
VCI132 from completely non-detectable to an apparent Kd of 8.1 ± 2.5 mM (Fig. 1.13B; Table 
1.1). A similar in-line probing experiment was carried out with radiolabeled VCI132LD as well. 
Results showed that VCII133 also rescues the glycine binding of VCI132LD from completely 
non-detectable to a Kd of 190 ± 41 µM (Fig. 1.13B; Table 1.1), enhanced ~40 fold further from 
that with VCI132. This affinity is substantially smaller than that of VCLD, unlike the glycine 
binding affinity of VCII133 rescued by VCI132LD. A possible explanation is that aptamer I 
requires the interaction between the P3b hairpin of aptamer II and the P1 helix of aptamer I (13, 
14, 18), which is right next to the break point in our in trans construct design. As evidenced by 
the two bands of the reconstituted complexes in native gel assays (Fig. 1.12A), in this non-
covalently linked version, kink-turn leader-linker interaction in the VC glycine riboswitch may not 
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be formed perfectly, leading to imperfect interaction between the P3b hairpin of aptamer II and 
the P1 helix of aptamer I and exhibiting only partial rescue of the glycine binding affinity. 
Combining the results of the trans in-line probing assays, we have demonstrated inter-
aptamer interactions can enhance the glycine binding affinities of the individual aptamers while 
the leader-linker interaction provides an additional 26 to 40 fold enhancement.  
 
Figure 1.13 Representative semi-log plots of aptamers rescuing each other in trans in-line 
probing assays.  
 
(A) r7 of VCII133 rescued by 15 µM of aptamer I constructs. (B) r2 of VCI132LD and VCI132 
rescued by 15 µM of VCII133. 
 
1.2.8 Full-length glycine riboswitch does not exhibit glycine binding cooperativity 
 
 We have shown that glycine binding and inter-aptamer interaction function 
synergistically in glycine riboswitch folding through trans assays with native gel and in-line 
probing experiments. There are two glycine binding sites and multiple inter-aptamer 
interactions, which may or may not take place concurrently. The leader-linker interaction forms 
in the absence of glycine, as indicated by the constant protection in the linker region in the in-
line probing assay and the lack of glycine perturbation in the HRFP experiments of the full-
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length glycine riboswitches. This seems to suggest that not all interactions are formed at the 
same time. One specific question is whether the two glycine molecules bind cooperatively. One 
crude measure is to use Hill coefficients of the glycine binding in the double aptamer 
riboswitches. Indeed, our results showed that the truncated VC and FN glycine riboswitches 
have Hill coefficient values larger than one, exhibiting reasonable apparent cooperativity, 
although smaller than reported (6, 13). Two linker mutants, VCLDLN and VCI-IILN which 
contain no leader-linker interaction, showed Hill coefficient values larger than one as well, 
exhibiting similar cooperativity to that of the truncated construct VCI-II. However, all three full-
length glycine riboswitches showed Hill coefficient mean values less than or close to one and 
the upper limits of these values are all close to one, exhibiting no glycine binding cooperativity. 
We recognize that Hill coefficient values are extremely sensitive to the accidental error of the 
data points and therefore may not be the definitive measure for glycine binding cooperativity. 
The unequivocal evidence of the glycine binding cooperativity of the truncated construct VCI-II 
is from mutation analysis. Breaker and coworkers reported that deleterious mutations in each 
aptamer greatly reduced the glycine binding affinities of the other aptamer, demonstrating inter-
aptamer inhibition and cooperativity between two glycine binding sites (6). Our results showed 
that VCI-IIG17C (nts 1 to 225, with G17C mutation)  not only completely abolished glycine 
binding in the aptamer I regions but also reduced the aptamer II glycine binding affinity to 1.1 ± 
0.1 mM while VCI-IIG146C binds glycine with a Kd of 1.9 ± 0.3 mM in both aptamers, 
comparable to the previous reports (6, 14). These experiments are consistent with the 
cooperative binding in the two glycine binding sites of the truncated glycine riboswitch VCI-II. To 
assess the glycine binding cooperativity of VCLD, we therefore constructed VCLDG17C (nts -7 
to 225, with G17C mutation) and carried out in-line probing experiments. Results showed that 
most of the aptamer I regions modulated in VCI-II and VCLD do not show glycine modulation in 
VCLDG17C, such as nts 63-64, 70-72, 74 (r2), 78-80, and 83 (Fig. 1.14A). However, much to 
our surprise, unlike VCI-IIG17C, the aptamer II regions including nts 146 (r5), 170-172 (r6), 177-
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178 (r7) and 207-208 showed strong glycine modulation with a Kd of 2.8 ± 0.4 µM, retaining full 
glycine binding capacity of VCLD in these regions (Fig. 1.14A,C; Table 1.1). Interestingly, A121-
G123 (r3) is also perturbed with a similar glycine binding affinity, consistent with our finding that 
aptamer II needs structural elements from aptamer I to bind glycine. We have also mutated 
aptamer II and constructed VCLDG146C (nts -7 to 225, with G146C mutation). In-line probing 
experiments showed that most of the aptamer II regions modulated in VCI-II and VCLD do not 
show glycine modulation in VCLDG146C, such as nts 170-172 (r6), 177-178 (r7), and 207-208 
(Fig. 1.14B). However, again unexpectedly, unlike VCI-IIG146C, the aptamer I regions including 
nts 70-72, 74 (r2), 78-80, and 121-123 (r3) showed great glycine modulation with a Kd of 12 ± 2 
µM, retaining most of the glycine binding capability of VCLD in these regions (Fig. 1.14B,D; 
Table 1.1). Interestingly, nt 146 (r5) is also perturbed with a similar glycine binding affinity, 
consistent with our finding that aptamer I needs structural elements from aptamer II to bind 
glycine (though clearly, in this case, the type of nucleobase is flexible). The in-line probing 
results of VCLDG17C and VCLDG146C showed that an individual glycine binding site may 
retain its full or majority binding capacity even though the other site is not occupied, abolishing 
inter-aptamer inhibition observed in VCI-II, and strongly suggesting that VCLD does not bind 
two glycine molecules cooperatively. 
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Figure 1.14 In-line probing gel images of VCLDG17C (A) and VCLDG146C (B). 
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. r2-r7 indicate regions defined in Table 1.2. (C) and (D) show the 
representative semi-log plots of the normalized fraction of RNA bound versus glycine 
concentration for VCLDG17C (r3, r5, and r6) and VCLDG146C (r2, r3, and r5), respectively. 
 
1.3 Discussion 
 
Prompted by the different protection patterns in the linker regions of two different 
truncated glycine riboswitches (VCI-II and VCI-IIs), we have identified a leader-linker interaction 
involving nucleotides upstream of the current published consensus glycine riboswitch 
sequences. This leader-linker interaction forms a P0 helix with 3-7 base pairs and is greatly 
conserved (>90%) in tandem glycine riboswitches. In more than half of the glycine riboswitches, 
the P0 helix is connected to the P1 helix through a kink-turn motif. These kink-turn motifs fit 
largely to the consensus kink-turns derived from the ribosome kink-turns, except that the base 
pair adjacent to the internal loop has a strong preference for G-C, just the opposite to the C-G 
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base pair preference in the ribosome kink-turns. The kink-turn motif is not unprecedented in 
riboswitches; it has been reported in SAM-I riboswitches connecting to the four-way junction 
motif (36) as well as in the class II c-di-GMP (37) and lysine riboswitches (38). This SAM-I kink-
turn motif follows the exact consensus derived from the ribosome kink-turns and is stabilized by 
RNA tertiary structure (39), different from those stabilized by metal ions (25) or protein binding 
(40, 41). It will be interesting to investigate which strategy is used in the glycine riboswitch to 
stabilize the kink-turn motif located at the 5’ boundary of this regulatory RNA. 
We have shown that full-length glycine riboswitches bound glycine 4.5 to 86 fold tighter 
than the truncated versions under saturating magnesium concentrations (16). Interestingly, 
three full-length glycine riboswitches, VCLD, FNLD and BSLD showed glycine binding affinities 
very similar to each other, unlike their truncated versions, raising the question whether glycine 
riboswitches have convergently evolved to bind glycine at a cellularly specific value for optimum 
metabolism. 
We have demonstrated direct binding between two aptamers in trans without any 
overlapping bases using native gel assays. The leader-linker interaction enhanced the inter-
aptamer interaction by at least 10 fold with the riboswitches saturated with glycine. As inter-
aptamer complexation cannot be detected by native gel assay in the absence of glycine, these 
results suggest that glycine binding enhances the inter-aptamer interaction. Conversely, 
aptamers also greatly enhanced the glycine binding ability of each other with the leader-linker 
interaction contributing an additional 26 to 40 fold improvement. These data suggest that inter-
aptamer interaction and glycine binding complement each other. One prominent property of the 
truncated glycine riboswitches is their glycine binding cooperativity. Surprisingly, the Hill 
coefficients of the wild-type full-length glycine riboswitches and more definitively the mutational 
analysis with VCLDG17C and VCLDG146C showed that there is no ligand binding cooperativity 
between two glycine binding sites in the full-length glycine riboswitches. 
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Together, our results support a new global folding model of the tandem glycine 
riboswitches. Independent of glycine, the leader-linker interaction can be formed in the presence 
of magnesium ions and leads to a more compact structure which enhances glycine binding and 
other inter-aptamer interactions, such as the α-α’, β-β’ and - ’ inter-aptamer interactions 
reported previously (14, 18, 19). The glycine binding at either site acts synergistically with inter-
aptamer interactions to achieve global folding of the tandem glycine riboswitch while the two 
glycine binding sites do not operate cooperatively. 
Our biochemical results focused on the VC glycine riboswitch and strongly supported the 
lack of glycine binding cooperativity in the full-length VC glycine riboswitch. Although we cannot 
rule out possible ligand binding cooperativity in other full-length glycine riboswitches, since the 
truncated construct VCI-II is the most cooperative glycine riboswitch reported our finding is likely 
to be general. The lack of glycine binding cooperativity in the full-length glycine riboswitches 
may have been manifested in the great variability of the reported cooperativity values with Hill 
coefficients ranging from 1.1 to 1.6 (6, 12-14, 16). 
One interesting question remains: without the advantage of cooperative and more 
“digital” response to the cellular glycine concentration, why do glycine-sensing RNAs evolve into 
the tandem arrangement? One possibility is that as our data pointed out, glycine-sensing may 
not be achieved efficiently with a single aptamer, given glycine is the smallest organic molecule 
sensed by RNAs. Individual aptamers need structural elements from other aptamers to achieve 
efficient glycine binding; the only reported functional wild-type single aptamer construct VCII122 
uses part of the aptamer I sequence to mimic an efficient glycine binding strategy. The 
protection pattern changes shown by r3 in VCLDG17C and r5 in VCLD146C also support this 
idea. Another possibility is that through tandem arrangement, the glycine riboswitch employs the 
leader-linker interaction to promote interaptamer interactions and preorganize the glycine 
binding pockets. Three experimental results support the more organized and compact structure 
formation in the absence of glycine: a) protection of the regions important for inter-aptamer 
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interaction or the glycine binding pocket is independent of glycine in HRFP of the full-length 
glycine riboswitches (Fig. 1.8, 1.9., 1.10); b) the longer VCLD runs slightly faster than VCI-II in 
the absence of glycine on native gel while running comparable or slightly slower than VCI-II in 
the presence of glycine (Fig. 1.15); c) two antibody fragments (Fabs) selected against VCI-II 
(42) bind VCLD with similar affinities but higher percentage binding at saturating Fab 
concentrations presumably because VCLD is less flexible and retained better during the 
washing step in the filter-binding assay (data not shown). The more compact and organized 
structure of full-length glycine riboswitches may have advantages in glycine-sensing under 
physiological conditions in vivo if fast on rate is desired similar to other riboswitches under 
kinetic control (15, 43, 44) 
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Figure 1.15 Native gel assay of glycine riboswitch compaction. 
 
6% non-denaturing PAGE in 5 mM MgCl2 and 5 mM glycine (A) and 5 mM MgCl2 and no glycine 
(B). These two gels were prepared in two different halves of the same gel cassette separated by 
a spacer to ensure identical running conditions. Lane 1 and 5, VCLD; Lane 2 and 6, VCI-II; Lane 
3 and 7, VCI-IIs; Lane 4 and 8, VCI-IIG146C. 
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1.4 Materials and Methods 
 
1.4.1 Preparation of the RNAs 
 
The glycine riboswitches VCI-II, FNI-II, BSI-II and single aptamers were generated by 
annealing DNA oligonucleotides (Integrated DNA Technologies) and amplified by recursive PCR 
with an EcoRI restriction site and T7 promoter sequence engineered at the 5’ terminus, and EarI 
and HindIII sites engineered at the 3’ terminus. Double digested riboswitch DNA inserts and 
pUC19 vector were ligated together to generate glycine riboswitch plasmids. The full-length 
glycine riboswitches and mutants were constructed by a similar method or QuikChange site-
directed mutagenesis (Stratagene) from the corresponding wild type plasmids and proper DNA 
oligonucleotide primers. The plasmids were transformed into JM109 cells, amplified and purified 
with Qiagen plasmid preparation kit, and their sequences confirmed by sequencing (Genewiz 
Inc). A Qiagen Midiprep produced more plasmid which was then linearized with EarI and 
transcribed by T7 RNA polymerase. The RNA transcripts were purified by 6% to 8% denaturing 
PAGE, electroeluted, PCA extracted, ethanol precipitated, and redissolved in TE buffer.  
1.4.2 In-line probing assay and quantification 
 
RNA transcripts were dephosphorylated with Shrimp alkaline phosphatase (Fermentas 
Life Sciences) and 5’ 32P labeled with  32P ATP (Perkin Elmer) and T4 polynucleotide kinase 
(New England Biolabs). For transcripts with the 5’ end buried by or too close to a duplexed 
region, to improve the labeling yield, the transcript was first annealed to a short DNA 
oligonucleotide to free the 5’ end before dephosphorylation and kinase reactions. In-line probing 
assays were carried out similar to the reported procedure (28). Briefly, ~50 kcpm 32P labeled 
RNA transcript was incubated at 25 oC for 48 h in 50 mM Tris-HCl (pH 8.3), 20 mM MgCl2, 100 
mM KCl under various glycine concentrations. For the trans in-line probing assay, 15 µM 
unlabeled proper aptamer was also added to the reaction. Spontaneously cleaved RNA 
fragments were resolved by 8% denaturing PAGE, dried, exposed to PhosphorImager screens, 
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and quantified by ImageQuant (Molecular Dynamics). For VC glycine riboswitches and mutants, 
the following regions are quantified if contained on the constructs and well-resolved: U74 (r2), 
A121-G123 (r3), G136-G137 (r4), G146 (r5), G170-A172 (r6), C177-A178 (r7), and U207-C208. 
To control for loading differences, the band intensities were normalized to nonvariable bands 
(U94 and U156-U161). For FN glycine riboswitches, the following regions are quantified if 
contained on the constructs and well resolved: G35, U46 (r2), G61 (r3), G85 (r5), G110-A112 
(r6), and C117-A119 (r7). Band intensities were normalized to nonvariable bands (U23 and 
C90). For BSLD and BSI-II, the following regions are quantified: G60, U83 (r2), C88-A89, A151-
A153 (r6), and A158-G160 (r7). Band intensities were normalized to nonvariable bands (G136-
U138). The Hill coefficients and dissociation constants were obtained by fitting each plot using 
the following equation in KaleidaGraph software: fraction bound = m1  [gly]
n/(Kd
n + [gly]n) + m2. 
1.4.3 Hydroxyl radical footprinting 
 
For footprinting, 5’ end labeled RNA was dissolved in 10 mM Na-MOPS (pH 7.0). 1 l of 
this RNA solution (~100 kcpm) was incubated with 1 l of 500 mM Na-MOPS pH 7, 1 l of 100 
mM MgCl2, 1 l of 10x stock glycine solution at various concentrations and 5 l of water for 20 
min at 50 oC. A 10x footprinting reagent was prepared separately that contained 1 mM 
Fe(NH4)2(SO4)2, 1.25 mM EDTA pH 8, and 60 mM sodium ascorbate.  To each sample, 1 l of 
this reagent was added to initiate the footprinting reaction. The reaction proceeded for 1 h at 
room temperature and was quenched by the addition of 5 l of thiourea stop solution (9 M urea, 
300 mM thiourea, 0.1% each xylene cyanol and bromophenol blue). The footprinting reactions 
were fractionated with 8% denaturing PAGE. The gels were dried, exposed to PhosphorImager 
screens, and quantified by ImageQuant (Molecular Dynamics). For VCI-II, the protections 
around G146 and G123 are quantified and normalized to nonvariable band C108. For FNI-II, the 
protections around G85-A86 and U65-C66 are quantified and normalized to nonvariable band 
G72. For BSI-II, the protection around C88 is quantified and normalized to nonvariable band 
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G75. The Hill coefficient and dissociation constant were obtained by fitting each plot using the 
following equation in KaleidaGraph software: fraction bound = m1  [gly]
n/(Kd
n + [gly]n) + m2. 
1.4.4 Native gel analysis of inter-aptamer complexation 
 
Native gel electrophoresis was carried out similar to the procedure described previously (14, 
35). 1 l of 5’ end labeled VCII133 (~5 kcpm) was incubated with 1 l of 2x incubation buffer 
(180 mM Tris-borate, pH 8.3, 10 mM glycine, 20 mM MgCl2) for 20 min at room temperature. In 
a separate Eppendorf tube, 1 l of 4x stock unlabeled VCI132 (or VCI132LD) solution at various 
concentrations was incubated with 1 l of 2x incubation buffer for 20 min at room temperature. 
The solution was combined together and incubated for an additional 20 min at room 
temperature. After homogenizing with 1 µl of 5x native loading dye (50% glycerol, 0.1% xylene 
cyanol), the reaction mixture was resolved via a 6% native PAGE in TB buffer containing 10 mM 
MgCl2 and 5 mM glycine. Electrophoresis was carried out with TB buffer containing 10 mM 
MgCl2 at 4 
oC for 4 h under approximately 12.5 V per cm of gel height. The gels were dried, 
exposed to PhosphorImager screens, and quantified by ImageQuant (Molecular Dynamics). The 
dissociation constant was obtained by fitting each plot using the following equation in 
KaleidaGraph software: fraction bound = m1  [RNA]/(Kd + [RNA]) + m2.  
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CHAPTER 2 DNA-RESCUABLE ALLOSTERIC INHIBITION OF APTAMER II LIGAND 
AFFINITY BY APTAMER I ELEMENT IN THE SHORTENED VIBRIO CHOLERAE 
GLYCINE RIBOSWITCH 
2.1 Introduction 
 
Synthetic biology utilizes engineered genetic circuits to reprogram or rewire organisms to 
achieve diverse functions, such as synthesis of cheaper drugs, generation of renewable fuels, 
and identification of disease mechanisms and viable drug targets (45, 46). Novel, inexpensive, 
and versatile genetic control elements are thus essential to the success of synthetic biology (45, 
46). Frequently, synthetic biologists turn to natural systems as inspiration for novel genetic 
control elements. Riboswitches are one class of naturally occurring genetic control elements 
which regulate gene expression by binding to small molecule metabolites independent of 
proteins (1, 47). Upon binding of the biologically important metabolites, riboswitches undergo 
conformational changes which may affect the structure of the associated expression platforms 
and control gene expression through transcriptional termination, translational initiation, or 
alternative splicing (1, 5, 47, 48). With increasing understanding of the gene control mechanism 
of riboswitches, researchers have designed and engineered several riboswitch-based genetic 
circuits (49, 50).  
Glycine riboswitches are of special interest as potential genetic control elements. 
Containing two tandem ligand-sensing domains, glycine riboswitches turn on downstream gene 
expression upon binding glycine molecules (6, 13, 19, 51-53). The glycine riboswitch from B. 
subtilis has been employed to express recombinant proteins using inexpensive glycine as an 
inducer with yields comparable to that in xylose- and IPTG-driven expression systems (54). 
Glycine riboswitches may offer more than just a model of a simple metabolite-sensing genetic 
control gate. Two versions of the glycine riboswitches have been reported in the literature. The 
biologically relevant full-length glycine riboswitches were reported recently by our group and the 
Das group (51, 52), in which the interaptamer linker forms a P0 duplex with the previously 
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unrecognized 5' leader sequence. In over 50% of known tandem glycine riboswitches, P0 
duplex complies with a kink-turn motif consensus which increases glycine affinity, allows further 
RNA compaction upon binding with kink-turn motif binding proteins, and abolishes glycine 
binding cooperativity (51-53). Interestingly, the previously reported glycine riboswitches lacking 
P0 duplex were reproducibly shown to bind two glycine molecules cooperatively (6, 12, 13, 16, 
17, 51). Experiments showed that deleterious single-nucleotide mutation to individual aptamers 
not only disabled the mutated aptamer, but also greatly reduced the glycine binding affinity of 
the other, indicating structure elements in one aptamer may control glycine binding  in the other 
through interaptamer interaction (6, 14, 18, 51). Further analysis of the P0-lacking glycine 
riboswitches may shed light on the molecular basis of the ligand-binding cooperativity and help 
design novel sophisticated biosensing genetic circuits for application in synthetic biology.  
In the present work, we choose to study the P0-lacking Vibrio cholerae glycine 
riboswitch (nts 1-225, referred to as VCIII hereafter) as this construct exhibits the highest ligand 
binding cooperativity, with a Hill coefficient of 1.64 (6). Our goal is to analyze the ligand binding 
cooperativity in greater detail and identify structure elements that are not only responsible for 
allosteric control of glycine sensing but also amenable for future design of novel genetic circuits. 
The Strobel group has proposed a sequential glycine binding model for the ligand 
binding cooperativity in VCIII glycine riboswitch (14). According to this model, one glycine 
molecule binds to the downstream aptamer II first and allows tertiary interactions to be made 
between the two aptamers, facilitating binding of a second glycine molecule to the upstream 
aptamer I, hence glycine-binding cooperativity. This model provides explanation for the 
inhibition of aptamer I’s glycine affinity by a deleterious mutation in aptamer II. However, this 
model does not provide explanation for the inhibition of aptamer II’s glycine affinity by a 
deleterious mutation in aptamer I, which has also been noted previously. Combining direct 
deletion studies, mutational analysis, and sequence examination, we have identified and verified 
an aptamer I element which effectively  controls  the  aptamer  II  glycine affinity, especially in 
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the shortened VC glycine riboswitch. Interestingly, the inhibitive effect of this structural element 
can be rescued with a short nucleic acid strand, restoring aptamer II glycine binding. This 
provides the possibility of engineering a shortened glycine riboswitch into a genetic control 
element that senses both glycine metabolite and a DNA input signal.  
2.2 Results  
 
2.2.1 5’-extended aptamer II construct VCII66 lost most of its glycine-binding affinity 
 
The sequential glycine binding model proposed by the Strobel group (14) provided 
explanation for the inhibition of aptamer I’s glycine affinity by a deleterious mutation in aptamer 
II of the P0-lacking VC glycine riboswitch. However, this model does not readily explain vice 
versa, the inhibition of aptamer II’s glycine affinity by a deleterious mutation in aptamer I. 
Breaker and coworkers showed that a deleterious mutation in aptamer I (VCIIIG17C, nts 1-225, 
G17C; Fig. 2.1, see figure legend for construct naming scheme) not only disabled the glycine 
binding affinity of aptamer I, but also greatly reduced the glycine binding affinity of aptamer II in 
the P0-lacking VC glycine riboswitch (6). This interaptamer inhibition, also reported by the 
Strobel group (14) and our group (51), is consistent with the ligand binding cooperativity in the 
P0-lacking VC glycine riboswitch (VCIII). Ligand binding cooperativity in a multi-subunit system 
typically suggests that binding to one site greatly enhances the binding at other sites (58). 
However, one version of the isolated aptamer II, VCII122, has been demonstrated to bind 
glycine even stronger than the double-aptamer riboswitch VCIII (59 ± 12 µM, Table 2.1) with a 
binding affinity of 4.4 ± 2.0 µM (Table 2.1) (51). The discrepancy between the glycine affinity of 
aptamer II in VCIIIG17C ([2.3 ± 0.5]  103 μM, Table 2.1, Fig. 2.2) and that in VCII122 suggests 
that certain structural elements may exist in aptamer I and interfere with aptamer II function 
when aptamer I is disabled or not fully formed. To test this hypothesis, we extended the 
sequence of aptamer II at the 5’ end to prepare the VCII66 construct (nucleotides, nts 66 225, 
Fig. 2.3), which contains the 3’ half of aptamer I, the linker between two aptamers, and the fully 
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functional aptamer II construct VCII122. As Kwon and Strobel (13) have indicated that P3a of 
aptamer I might be important to the glycine binding cooperativity in VCIII, we included the 5’ half 
of the P3a helix (nts 66 69) to accommodate the whole P3a helix in the construct. The glycine-
binding affinity of VCII66 was then evaluated via in-line probing assays which map local 
structure changes by measuring the flexibility of the phosphodiester bond to achieve in-line 
geometry for non-enzymatic cleavage through internal transphosphorylation (27, 28). Results 
showed that the glycine affinity of VCII66 as calculated from aptamer II regions (Fig. 2.1) is 
much weaker than that of VCII122, with a Kd value of (1.1 ± 0.3)  10
3 μM (Table 2.1, Fig. 2.3). 
The weaker binding affinity could also result from a mixture of multiple folding species in which 
the misfolded species may exhibit high cleavage background and mask the cleavage pattern of 
the correctly folded species. The overall protection pattern of VCII66 in 100 mM glycine is 
similar to that of VCII122 in the overlapping regions (Fig. 2.3), indicating that aptamer II folds 
into similar overall structures in these two constructs at saturating glycine concentrations. In 
addition, we have analyzed the riboswitch folding under in-line probing conditions with native gel 
electrophoresis. Results confirmed that VCII66 folds into a single species (Fig. 2.4 Lane 1). 
Combined together, these experiments suggest that there are critical structural elements 
between nt 66 and nt 122 interfering with glycine affinity of aptamer II in VCII66. 
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Table 2.1 Binding affinities of glycine riboswitches and mutantsa 
RNA Kd (µM) Description of the constructs 
VCII122 4.4 ± 2.0b  nts 122 to 225 
VCIII 59 ± 12b nts 1 to 225 
VCIIIG17C (2.3 ± 0.5)  103 nts 1 to 225, G17C 
VCII66 (1.1 ± 0.3)  103 nts 66 to 225 
VCII81 6.1 ± 1.9 nts 81 to 225 
VCII73 (1.5 ± 0.2)  103 nts 73 to 225 
VCIIIG17CM1 (1.3 ± 0.5)  103 nts 1 to 225, G17C, CUUU75-78AAAA 
VCII66P3a 
Misfold: (1.5 ± 0.3)  
103 Correct fold: 15.5 
± 4.2 
nts 66 to 225, GAAG66-69UUUU, CUUU75-
78AAAA 
VCII73M1 
Misfold: (2.5 ± 1.1)  
103 Correct fold: 34.0 
± 31.6 
nts 73 to 225, CUUU75-78AAAA 
VCIIIG17CP3a (1.2 ± 0.2)  103 
nts 1 to 225, G17C, GAAG66-69UUUU, CUUU75-
78AAAA 
VCII73 
(+DNA) 
12.5 ± 5.8 nts 73 to 225, with 12 µM complementary DNAc 
a Determined by in-line probing assays. Binding affinities were calculated as average Kd values 
(and ± their standard deviation) obtained from the individual glycine perturbed regions with 
curve fit coefficients better than 0.97 in at least two independent trials. 
b Data were taken from Sherman et al. 2012, RNA, 496-507. 
c Complementary oligodeoxynucleotide sequence is ACCTGAAAGATCAGAT. 
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Figure 2.1 Secondary structure of the P0-lacking VC glycine riboswitch (VCIII).  
 
r2 r8 indicate the representative glycine induced perturbation regions in the in-line probing 
assay of VCIII; the corresponding nucleotides are either circled or boxed with a square, which 
represents either decreased cleavage or increased cleavage with increasing glycine 
concentration, respectively. “I” and “II” refer to upstream aptamer I and downstream aptamer II, 
connected by a short linker. Definitions of construct lengths/mutations are given in the figure.  
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Figure 2.2 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCIIIG17C.  
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. r5-r6 indicate regions defined in Fig. 2.1. 
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Figure 2.3 Glycine affinity of VCII66 is drastically reduced compared to that of VCII122.  
 
A) Secondary structure of VCII66. r5 r8 and circled nucleotides are the same as defined in Fig. 
2.1. B) Representative semi-log plots of the normalized fraction of RNA bound versus glycine 
concentration for r5 and r6 of VCII66. C) In-line probing gel image of VCII66. NR indicates no 
reaction.  
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Figure 2.4 Native gel of 5’ 32P radiolabeled RNA constructs. 
 
This shows the existence of a single species for each construct, with the exception of lane 2 and 
4 showing an additional slower migrating band. Lane 1, VCII66; Lane 2, VCII66P3a; Lane 3, 
VCII73; Lane 4, VCII73M1; Lane 5, VCII81; Lane 6, VCIIIG17CP3a; Lane 7, VCIIIG17C; Lane 
8, VCIIIG17CM1.  
 
2.2.2 Identification of potential interaptamer interaction inhibiting the glycine affinity of 
VCII66 
 
We denote the aptamer I structural element that interferes with aptamer II glycine 
binding as Region A, which is likely to interact with a specific region (or several regions) in 
aptamer II denoted Region B in the absence of glycine to reduce Region B’s ability to participate 
in native structure formation and consequently decrease aptamer II’s glycine affinity. 
Accordingly, in the in-line probing assays of VCIII or VCII66, Region B may interact with Region 
A in the absence of glycine while participating in the native structure formation in the presence 
of glycine. Thus, the in-line probing cleavage pattern of a potential Region B may appear to be 
unperturbed or only marginally perturbed at different glycine concentrations as either in the 
presence or in the absence of glycine it is structured. For VCII122, however, as Region A is not 
present in the construct, Region B may show structural perturbation from less structured in the 
absence of glycine to more structured in the presence of glycine. We compared the in-line 
probing patterns of the aptamer II regions in VCIII and VCII66 with that of VCII122 (Figures 1 
1      2     3      4      5     6    7     8 
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and S2 in the report by Breaker and coworkers (6) and our in-line probing results) and found 
that nts 147 150 (AGAG) is the best region fit to this description of a candidate Region B. 
Examination of the corresponding regions in two other well-characterized glycine riboswitches 
from Bacillus subtilis (6) and Fusobacterium nucleatum (13) reveals the identical AGAG 
sequence; thusly nts 147-150 (AGAG) in VCIII is chosen as Region B. As long-range 
interactions in RNA structure involving a stretch of nucleotides often are through duplex 
formation with Watson-Crick or Wobble base pairs, such as kissing-loop interactions (33, 38, 59, 
60) pseudoknots (60-63), etc., we postulated that Region A and Region B may interact through 
a simple duplex formation. Considering both Watson-Crick and Wobble pairing, Region B 
(AGAG) could pair with CUCU, CUUU, UUCU or UUUU. Searching the primary sequence of 
VCIII with these four short oligonucleotide sequences, we found three candidates in aptamer 1: 
nts 35 38 (UUUU), nts 75 78 (CUUU), nts 91 94 (UUCU). Comparing the corresponding 
sequences in the glycine riboswitches from Bacillus subtilis and Fusobacterium nucleatum, we 
found that only nts 75 78 is conserved to pair with Region B. Importantly, nts 75 78 locates 
between nt 66 and nt 122 as predicted in the previous section. Therefore, nts 75-78 (CUUU) is 
assigned as Region A in VC glycine riboswitch. Furthermore, nts 75 78 (CUUU) and nts 
147 150 (AGAG) locate in the highly conserved regions of the 3’ half of the P3a helix on 
aptamer I and J1/2 of aptamer II, respectively, strengthening their potential functional roles as 
Region A and Region B. 
2.2.3 Verification and characterization of the inhibitory effect of Region A on aptamer II 
function in the shortened glycine riboswitch 
 
First, we prepared a construct VCII81 (nts 81 225, Fig. 2.5A), removing the entire 
predicted Region A and taking advantage of the consecutive guanosines at position 81 and 82 
for efficient in vitro transcription. If Region A is fully removed in this construct, we expect VCII81 
to significantly rescue glycine binding affinity; in-line probing assays were used to determine the 
glycine binding Kd of VCII81. Results (Figures 2.5B and 2.5C) showed that VCII81 retains the 
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full ligand binding capacity of VCII122 with a Kd of 6.1 ± 1.9 µM (Table 2.1), consistent with the 
complete removal of Region A. Native gel electrophoresis results confirmed that VCII81 folds 
into a single species (Fig. 2.4 Lane 5).  Interestingly, in the cleavage pattern of the in-line 
probing assay of VCII81 (Fig. 2.5C), in addition to the expected glycine perturbed regions r5 r8, 
we observed that nts 123 133 and nt 135 exhibit glycine-induced structural perturbation with 
similar glycine affinities. These observations rationalize the loss of glycine affinities in aptamer II 
for glycine riboswitches shorter than VCII122 reported previously (51). Particularly, nts 123 124 
are located within region r3, a glycine-perturbed single stranded aptamer I region in the double-
aptamer glycine riboswitches. Observation of glycine-induced structural perturbation in this 
region for VCII81 is reminiscent of the similar observation in the previously reported VCLDG17C 
construct (nts -7 225, G17C), in which region r3 exhibits similar glycine-induced structural 
perturbation as other aptamer II regions (r5 r7) although aptamer I is disabled (51). These 
results, combined together, confirm that aptamer II requires structural elements from aptamer I 
to bind glycine properly. In turn, this also rationalizes the potential existence of the aptamer I 
region (Region A) to modulate the glycine affinity of aptamer II.   
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Figure 2.5 VCII81 retains glycine binding affinity of VCII122.  
 
A) Secondary structure of VCII81. r5 r8 and the nucleotides circled or boxed with a square are 
the same as defined in Fig. 2.1. Additional glycine induced perturbation regions nts 123 133 
and nt 135 are also denoted. B) Representative semi-log plots of the normalized fraction of RNA 
bound versus glycine concentration for r7, r6, and U128 of VCII81. C) In-line probing gel image 
of VCII81. NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial  
digestion with alkali, respectively. 
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The difference in the glycine binding affinities between VCII66 and VCII81 suggests that 
the structural elements modulating aptamer II function locate between nt 66 and nt 80, which 
contains the predicted Region A (nts 75 78, the 3’ half of P3a), L3a, and the 5’ half of P3a. To 
test whether L3a and the 5’ half of P3a are responsible for modulating aptamer II function, we 
have prepared a construct VCII73 (nts 73 225), removing the 5’ half of P3a and L3a. In-line 
probing experiments showed that VCII73 binds glycine much more weakly than VCII122 or 
VCII81 with a Kd value around (1.5 ± 0.2)  10
3 μM (Table 2.1, Fig. 2.6), even weaker than 
VCII66. Similar to VCII66, native gel electrophoresis showed that VCII73 folds into a single 
species (Fig. 2.4 Lane 3), ruling out of the possibility of a masking effect of a misfolded species. 
The weaker affinity of VCII73 compared to VCII66 may be due to the fact that the 5’ portion of 
the P3a stem is no longer present in VCII73 (as it is in VCII66) to competitively duplex with 
Region A, allowing Region A to inhibit aptamer II function even further through better interaction 
with Region B. 
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Figure 2.6 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCII73.   
 
r5-r8 indicate regions defined in Fig. 2.1. 
 
Another way to verify the inhibitory effect of Region A on aptamer II glycine binding is to 
directly mutate Region A in VCII66 or VCII73 to prevent the interaction between Region A and 
Region B and analyze whether there is any rescue in aptamer II glycine affinity. We therefore 
prepared mutants VCII73M1 (nts 73 225, CUUU75-78AAAA) and VCII66P3a (nts 66 to 225, 
GAAG66-69UUUU, CUUU75-78AAAA). Here VCII66P3a contains extra mutations GAAG66-
69UUUU to maintain possible P3a duplex formation. We then analyzed the glycine binding 
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properties of these constructs with in-line probing assays. Unfortunately both constructs exhibit 
two glycine induced transitions, making it difficult to evaluate the glycine affinity of these 
constructs. Native gel electrophoresis showed that in addition to the band at the expected 
location, a new slower migrating band was observed for each of these two constructs (Fig. 2.4 
Lane 2 and Lane 4). We attribute this second species to either a simply misfolded or oligomeric 
form that may exhibit glycine induced transition at a higher glycine concentration. In-line probing 
data fit quite well with the equation describing two independent glycine-folded species (Methods 
section). The correctly folded species showed a glycine affinity of 15.5 ± 4.2 µM for VCII66P3a 
(Fig. 2.7) and 34 ± 32 µM for VCII73M1 (Fig. 2.8), both exhibiting a significant rescue from their 
parent constructs (Table 2.1). 
Collectively, these results confirmed the predicted Region A (nts 75 78) to be the 
structural element responsible for inhibiting aptamer II glycine affinity. In addition, Region A is 
solely responsible for the inhibition without the need for loop L3a or P3a duplex formation. 
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Figure 2.7 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCII66P3a.  
 
NR represents no reaction. r5-r8 indicate regions defined in Fig. 2.1. 
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Figure 2.8 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCII73M1.  
 
r5-r8 indicate regions defined in Fig. 2.1. 
 
2.2.4 Characterization of the interaptamer effect of Region A in double aptamer glycine 
riboswitches 
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double aptamer glycine riboswitches. According to the crystal structure of the glycine 
riboswitches (18, 19), the corresponding Region A directly participates in the glycine binding 
pocket of aptamer I. This means direct mutation of Region A on the wild-type double aptamer 
VCIII glycine construct will likely diminish or disable aptamer I glycine binding, making it difficult 
to precisely dissect the effect of Region A on aptamer II glycine affinity as deleterious mutation 
in aptamer I was demonstrated to reduce the glycine affinity in aptamer II previously (6, 13, 51). 
To circumvent this complication, we have examined the effect of Region A on the double-
aptamer VC glycine riboswitch (VCIII) in the presence of G17C mutation, which rendered 
aptamer I incapable of binding glycine regardless of the presence or absence of Region A. As 
reported previously (6, 13, 51), mutation in VCIIIG17C disables aptamer I function and greatly 
reduced the glycine affinity of aptamer II. If Region A remains functional and modulates the 
glycine binding activity of aptamer II in VCIIIG17C, one would expect that a mutation in Region 
A would remove this modulation and rescue the glycine affinity in aptamer II. We therefore 
prepared VCIIIG17CM1 (nts 1-225, G17C, CUUU75-78AAAA) and analyzed its glycine binding 
properties. Native gel showed that VCIIIG17CM1 folded into a single species similar to 
VCIIIG17C (Fig. 2.4 Lane 7 and Lane 8 ) and in-line probing experiments showed that mutation 
in Region A had a modest rescuing effect (~2 fold) and increased the  glycine affinity of aptamer 
II in VCIIIG17CM1 to (1.3 ± 0.5)  103 μM (Fig. 2.9A, Fig. 2.10) from (2.3 ± 0.5)  103 μM in 
VCIIIG17C. In addition, we prepared VCIIIG17CP3a (nts 1-225, G17C, GAAG66-69UUUU, 
CUUU75-78AAAA) which contains additional mutations to maintain a possible P3a duplex.  
Native gel showed that VCIIIG17CP3a folded into a single species (Fig. 2.4 Lane 6) and in-line 
probing experiments showed that VCIIIG17CP3a bound glycine with a modestly rescued affinity 
of (1.2 ± 0.2)  103 μM (Fig. 2.11), similar to VCIIIG17CM1. 
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Figure 2.9 Effect of Region A on the glycine binding affinity of aptamer II.  
 
Representative semi-log plots of the normalized fraction of RNA bound versus glycine 
concentration for r6 of VCIIIG17CM1 compared to that of VCIIIG17C (A) and VCII73 compared 
to VCII81 (B). 
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Figure 2.10 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCIIIG17CM1.  
 
r5-r6 indicate regions defined in Fig. 2.1. 
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Figure 2.11 Representative in-line probing gel image and semi-log plots of the normalized 
fraction of RNA bound versus glycine concentration of VCIIIG17CP3a.  
 
NR, T1, and OH represent no reaction, partial digestion with RNase T1, and partial digestion 
with alkali, respectively. r5-r6 indicate regions defined in Fig. 2.1. 
 
The drastically different modulating effect of Region A in the two versions of constructs, 
VCIIIG17C vs. VCIIIG17CM1/VCIIIG17CP3a (~2 fold modulation, Fig. 2.9A, Table 2.1) and 
VCII73 versus VCII81 (~200 fold modulation, Fig. 2.9B, Table 2.1), shows that Region A 
modulates aptamer II activity in a context dependent manner and truncation has a large effect 
on the interaptamer interaction and glycine binding. In the context of the double-aptamer glycine 
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riboswitches, Region A plays a partial but not a sole role in the interaptamer inhibition of 
aptamer II. What else can cause the interaptamer inhibition of aptamer II in the double-aptamer 
glycine riboswitches? It is possible that when the aptamer I glycine binding site is not occupied, 
interaptamer interaction is not formed properly for optimum glycine binding in the aptamer II site. 
This is not completely surprising as we have demonstrated that glycine binding acts 
synergistically with interaptamer interaction in the glycine riboswitch (51). The smaller rescuing 
effect of Region A mutation in the double-aptamer glycine riboswitch may be more biological 
relevant to the naturally occurring glycine riboswitch, where the full-length P0-containing VC 
glycine riboswitch does not exhibit glycine binding cooperativity (51, 53). However, this result 
also shows that the shortened VC glycine riboswitch VCII73 is more suitable for future 
engineering into a novel genetic circuit. 
2.2.5 Allosteric inhibition of aptamer II function by Region A may be rescued by a DNA 
oligonucleotide 
 
Our finding of the inhibitory role of Region A on aptamer II glycine affinity in the 
shortened VC glycine riboswitch is intriguing, for the ~200 fold effect provides a good window 
for potential gene expression control. However, in order to harness this effect, we need to be 
able to reverse this inhibition by an exogenous effector, a signal that can be sensed by an in 
vitro or in vivo system based upon this in the future. Therefore, we investigated whether the 
modulation effect of Region A on aptamer II can be rescued by such a simple input signal. Our 
previous analysis indicates that Region A may regulate aptamer II function by duplexing with 
sequences on aptamer II; unsurprisingly, this suggests that a short nucleic acid strand 
complementary to Region A may competitively remove the inhibitory effect and rescue the 
glycine binding affinity of aptamer II. To test this, the glycine binding affinity of VCII73 in the 
presence of complementary oligodeoxynucleotide (ACCTGAAAGATCAGAT, Fig. 2.12A) was 
determined with in-line probing. Results showed that in the presence of 12 µM complementary 
oligodeoxynucleotide, VCII73 exhibited a similar glycine perturbation pattern as VCII81 and 
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bound glycine with an affinity of 12.5 ± 5.8 µM (Figures 2.12B and 2.12C). This corresponds to a 
120-fold increase of glycine affinity from that of VCII73 and an almost complete restoration of 
the glycine affinity of VCII81. 
 
Figure 2.12 The glycine binding affinity of VCII73 can be rescued by the addition of a 
complementary oligodeoxynucleotide.  
 
A) Secondary structure of VCII73 when annealed to complementary oligodeoxynucleotide 
ACCTGAAAGATCAGAT. r5 r8 and the nucleotides circled or boxed with a square are the same 
as defined in Fig. 2.1. Additional glycine induced perturbation region nts 123 133 are also 
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denoted as defined in Fig. 2.1. B) Representative semi-log plots of the normalized fraction of 
RNA bound versus glycine concentration for r7, r6, and U128 of VCII73 rescued by 
complementary oligodeoxynucleotide ACCTGAAAGATCAGAT. C) In-line probing gel image of 
VCII73 rescued by complementary oligodeoxynucleotide ACCTGAAAGATCAGAT. NR 
represents no reaction. 
2.3 Discussion 
 
Glycine riboswitches are most often located upstream of the gcvTHP operon controlling 
the expression of the glycine cleavage system (6, 7), which breaks down glycine and produces 
carbon dioxide, ammonia, and 5-10-methylenetetrahydrofolate in the presence of 
Tetrahydrofolate (8). 5-10-methylenetetrahydrofolate can also serve as a source of methyl 
groups for methionine, serine, and 2’-deoxythymidine (9). Glycine riboswitches have also been 
identified upstream of the glcB gene in the most abundant marine bacterium Candidatus 
Pelagibacter ubique (12), controlling the expression of malate synthetase which makes malate 
from exogenous glycine derivatives. These show that naturally occurring glycine riboswitches 
are important regulators of carbon metabolism in bacteria. Besides the natural gene control 
functions, glycine riboswitches have been used for controllable overproduction of recombinant 
proteins using the inexpensive glycine inducer (54). This has demonstrated application of the 
glycine riboswitch as a general genetic control element. However, the ligand binding 
cooperativity in the P0-lacking glycine riboswitch suggests that this system may be able to offer 
more than just a basic metabolite-sensing genetic control gate to synthetic biology. 
In this work we have identified a structural element (Region A) located in aptamer I that 
regulates the ligand binding affinity of aptamer II in the shortened glycine riboswitches, VCII66 
and VCII73. Removal of Region A from VCII73 resulted in a construct VCII81 which showed 
fully restored (~200 fold rescue) glycine binding affinity. The interaction partner of Region A in 
aptamer II is proposed as Region B (nts 147-150) for this aptamer II modulation. However, this 
is not experimentally tested because the proposed Region B is highly conserved, and the 
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mutations in Region B are likely to diminish the glycine affinity of aptamer II, making any rescue 
of aptamer II's glycine affinity due to the disruption of Region A and B interaction unobservable. 
Interestingly, a short oligodeoxynucleotide complementary to Region A and neighboring 
nucleotides can rescue the glycine binding activity of VCII73 by ~120 fold. Given the 
demonstrated importance of the gene control functions of natural and synthetic glycine 
riboswitches, our findings could pave the path for developing a new genetic circuit sensing two 
mechanistically distinct signals, a short nucleic acid strand and small molecule metabolite 
(glycine). 
2.4 Materials and Methods  
 
2.4.1 DNA constructs of the RNAs 
 
The VC glycine riboswitch genes were generated by recursive PCR (55) from DNA 
oligonucleotides (Integrated DNA Technologies) with EcoRI restriction site and T7 promoter 
sequence engineered at the 5’ terminus, and EarI and HindIII sites engineered at the 3’ 
terminus similar to that described previously (56). Double digestion of the riboswitch DNA genes 
with EcoRI and HindIII (New England Biolabs) was then performed in the supplied NEB buffer 2 
at 37°C for 1 hour. Double digested riboswitch DNA genes and pUC19 vector were ligated 
together using T4 DNA ligase (New England Biolabs) in the supplied T4 DNA ligation buffer at 
16°C with overnight incubation to generate glycine riboswitch plasmids as reported previously 
(42). The glycine riboswitch mutants were constructed either by a similar method or by 
QuikChange site-directed mutagenesis (Stratagene) from the corresponding wild type plasmids 
and proper DNA oligonucleotide primers. These plasmids were transformed into JM109 cells, 
amplified, purified with Qiagen plasmid preparation kits, and sequenced by Eton Bioscience Inc. 
In vitro transcription for the preparation of RNAs 
Riboswitch plasmids were linearized by incubation with EarI (New England Biolabs) at 
0.2 unit per µg of plasmid in the supplied NEB buffer 4 at 37°C overnight. RNAs were 
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transcribed in 1 ml reaction mixture containing 40 mM Tris-HCl (pH 7.9), 2 mM spermidine-
3HCl, 10 mM DTT, 25 mM MgCl2, 5 mM each of the nucleotide triphosphates, 50 µg/ml  
linearized plasmid, 0.01 unit/µl 5 PRIMETM stop RNase inhibitor RX (5 PRIME life science), 8 
miliunit/µl thermostable inorganic pyrophosphatase (New England Biolabs), and 45 µg/ml T7 
RNA polymerase (expressed and purified in-house) and incubated overnight at 37°C. The 
transcription mixture was incubated with 1 mM CaCl2 and RNase-free DNase I (Promega) at a 
concentration of 0.5 unit per µg of DNA plasmid at 37°C for 30 minutes. The RNA transcripts 
were purified by 6-8% denaturing polyacrylamide gel electrophoresis, isolated by UV shadowing 
and excised, electroeluted into TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA), PCA extracted, 
ethanol precipitated, and resuspended in TE buffer. RNA concentrations were determined by 
UV absorbance at 260 nm wavelength with extinction coefficients calculated by OligoCalc (57). 
5’ end 32P labeling of RNAs 
 
In a typical procedure, 40 pmol RNA transcript was dephosphorylated by incubation with 
1 unit of shrimp alkaline phosphatase (Fermentas Life Sciences) in the supplied phosphatase 
buffer in a total volume of 10 µl at 37 oC for 30 min. After incubation at 65 oC for 15 min to 
inactivate the phosphatase, 1 µl sterile H2O, 1.5 µl 10x T4 polynucleotide kinase buffer (New 
England Biolabs), 2 µl -32P ATP (Perkin Elmer), and 0.5 µl 10 unit/µl T4 polynucleotide kinase 
(New England Biolabs) were added and the reaction mixture was incubated at 37 oC for 30 min 
for RNA phosphorylation. For RNA transcripts with the 5’ end buried by or too close to a duplex 
region, to improve the labeling yield, the transcripts were first annealed to a DNA 
oligonucleotide to free the 5’ end before dephosphorylation and phosphorylation reactions. For 
example, to radiolabel the 5' end of VCII81 (nts 81-225), 40 pmol VCII81 was first incubated 
with 1.05 eq of an annealing oligonucleotide (AACTACAGTCCTCGCTTATTC) at 95 oC for 1 
min, then at room temperature for 10 min before dephosphorylation and phosphorylation 
reactions. After phosphorylation, 32P-labeled RNAs were purified by 6-8% denaturing 
polyacrylamide gel electrophoresis, visualized on an x-ray film, excised, and passively eluted in 
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300 µl TE buffer on a rotator at 4 oC overnight. After centrifugation, the radiolabeled RNAs were 
PCA extracted twice, precipitated with ethanol, and redissolved in TE buffer. 
2.4.2 In-line probing assays and quantification 
 
 In-line probing assays were carried out similar to the reported procedure (28). Briefly, 
~50 kcpm 32P labeled RNA transcript was incubated at 25 oC for ~48 h in 50 mM Tris-HCl (pH 
8.3), 20 mM MgCl2, 100 mM KCl under various glycine concentrations. For the in-line probing 
assays of VCII73 in the presence of complementary oligodeoxynucleotide 
(ACCTGAAAGATCAGAT), 12 µM complementary oligodeoxynucleotide was first annealed with 
50 kcpm 5’ 32P radiolabeled VCII73 by incubation at 95 oC for 1 min and then room temperature 
5 min before addition of MgCl2 and KCl. After 48 h incubation at 25 
oC, spontaneously cleaved 
RNA fragments were resolved by 8% denaturing PAGE, dried, exposed to PhosphorImager 
screens, scanned by PhosphorImager SI (Molecular Dynamics), and quantified by ImageQuant 
v5.2 (Molecular Dynamics). For VC glycine riboswitches and mutants, the following regions are 
quantified if contained on the constructs and well-resolved: U74 (r2), A121-G123 (r3), nts 124-
133 (for VCII81, and VCII73 when rescued by a complementary oligodeoxynucleotide), G136-
G137 (r4), G146 (r5), G170-A172 (r6), C177-A178 (r7), and U207-C208. To control for loading 
differences, the band intensities for tight binding constructs (Kd < 100 µM, including VCII66P3a 
and VCII73M1) were normalized to reference bands (U156-U161). The reference bands do 
occasionally show small perturbation which has little effect on the glycine affinity of the tight 
binding constructs but can notably affect weak binders (Kd > 500 µM); to avoid this, weak 
binders were not normalized. Kd values of the individual glycine-perturbed regions were 
determined by non-linear regression fitting of each plot using the following equation in 
KaleidaGraph software v3.09 (Synergy Software): fraction bound = m1  [gly]/(Kd + [gly]) + m2. 
The reported binding affinities were calculated as average Kd values obtained from the 
individual glycine-perturbed regions with curve fit coefficients better than 0.97 in at least two 
independent trials. For constructs that exhibit two glycine induced transition due to two 
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independent folding species, the following equation was used:  fraction bound = m1  [gly]/( Kd1 + 
[gly]) + m2  [gly]/( Kd2 + [gly]) + m3. 
2.4.3 Native gel electrophoresis 
 
5’ radiolabeled RNA was folded by the following procedure: 1 µl 20 µM RNA was added 
to 7 µl 10 mM Tris-HCl (pH 7.5) and incubated at room temperature for 2 min. The VCII73 
rescue DNA oligo, where used, was also added to the mixture and incubated at either room 
temperature or 95 oC for 2 min. 1 µl 100mM MgCl2 and 1 µl 0.1 M glycine were added to the 
mixture, followed by incubation at room temperature for 20 min. This mixture was then 
combined with 2 µl native gel loading dye (50%v/v glycerol, 0.1%w/v xylene cyanol) and loaded 
onto a 6% native polyacrylamide (29:1 acrylamide:bisacrylamide) gel in TB buffer (89 mM Tris 
base and boric acid) containing 5 mM MgCl2 and 5 mM glycine. The electrophoresis setup was 
prerun with TB buffer containing 5 mM MgCl2 for two hours at constant 25 W and conducted for 
additional 3.5 hours after sample loading at 4oC with constant 250 V. The gel was dried, 
exposed to PhosphorImager screens, scanned with PhosphorImager SI (Molecular Dynamics), 
and analyzed by ImageQuant v5.2 (Molecular Dynamics).  
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CHAPTER 3 SPECIFIC RNA-BINDING ANTIBODIES WITH A FOUR AMINO ACID 
CODE 
3.1 Introduction 
 
Recent advances in genomic and next-generation sequencing have greatly accelerated 
the discovery of non-protein coding RNAs (ncRNAs) (64, 65). Revealed by high-throughput 
methods, the observation that 90% of the human genome is transcribed while only 2% is 
protein-encoding suggests that the human transcriptome likely provides a rich spectrum of non-
coding sequences to expand the RNA function repertoire (66). For example, small ncRNAs such 
as microRNAs have greatly shaped our view of posttranscriptional gene regulation (67).     
The structurally more complex ncRNAs are RNAs with larger sizes ranging from about 
one hundred bases to several kilobases, including long non-coding RNAs (lncRNAs) from the 
eukaryotic genomes (66, 68), as well as riboswitches (1) and the exceptional structured ncRNAs 
(69) from bacteria. Aided by computational methods (66) and experimental approaches such as 
cDNA cloning and gene tiling arrays (70), thousands of large ncRNAs are reported each year 
(68). They play key roles in a wide range of functions, including transcriptional regulation, 
translational control, epigenetics,  stem  cell  biology,  cancer, signaling, and  brain  function (1, 
68, 71, 72). 
To carry out their biological functions, the large ncRNAs typically adopt extensive 
secondary and tertiary structures and often interact with a partner, such as a protein, RNA, 
ribonucleoprotein complex, metal ion, or metabolite (48, 68, 73). The structured nature of most 
large ncRNAs renders them suitable targets for specific recognition by well-characterized 
proteins, such as antibody fragments (42, 74). We are particularly interested in using specific 
antibody recognition to assist the structural and functional studies of ncRNAs for the following 
reasons. 
First, antigen binding fragments (Fabs) when complexed with RNAs may help elucidate 
RNA structures (74, 75). Elucidating the structures of ncRNAs with unknown functions may 
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provide important clues towards revealing their functions and the molecular mechanisms behind 
their functions. However, detailed tertiary structure of large ncRNAs often requires high-
resolution crystal structures that are generally difficult to obtain (42, 76, 77). Chaperone-
assisted RNA crystallography (CARC) represents one promising method which employs an 
antibody fragment to bind RNAs, aiding in crystallization through extensive crystal contact 
participation as well as facilitating the structure solving process by providing superior initial 
phasing information (74, 75).  
Secondly, targeting structured ncRNAs with antibodies (or antibody fragments) may 
provide potential therapeutics for cancer or other human diseases involving RNA causative 
agents. Numerous lncRNAs have been shown to lead to tumorigenesis. The lncRNA HOX 
transcript antisense RNA (HOTAIR), for instance, targets polycomb repressive complex 2 
(PRC2) genome-wide to alter H3K27 methylation and gene expression patterns, resulting in 
increased cancer invasiveness and metastasis in breast carcinomas (78). A new class of 
ncRNAs, the transcribed ultraconserved regions (T-UCRS), has been shown to be abnormally 
expressed in a number of human cancers such as leukemia, colorectal carcinoma and 
hepatocellular carcinoma (79-82). Besides carcenogenicity, large ncRNAs are also implicated in 
non-neoplastic diseases, such as Alzheimer’s disease (83), neurodeveloplemtal disorders (84), 
and imprinting disorders (85). Targeting these disease-associated RNAs with antibody 
fragments may provide diagnostic or therapeutic tools in the future. 
In addition, RNA-binding antibodies may be used to help discover interaction partners of 
ncRNAs by immunoprecipitating the RNAs directly or to determine cellular distribution of 
ncRNAs through imaging fluorescently labeled RNA-binding antibodies (74, 86). 
Recent advances in antibody phage display have led to facile production of antibodies 
binding to proteins in vitro without the expensive and laborious hybridoma approach (87-89). 
Using a phage platform that displays Fab libraries with naïve synthetic repertoires, we have 
recently established a general approach to obtain Fabs binding to structured RNAs (42, 74, 75). 
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Using the YSGX and YSGRX libraries, we have obtained Fabs that specifically recognize and 
co-crystallize the P4-P6 domain of the self-splicing Group I intron from Tetrahymena (74) and 
the synthetic class I ligase (75).  
However, neither the YSGX nor YSGRX library was designed specifically for RNA 
recognition: their success in RNA antibody production has been limited with much potential for 
improvement. Although successful with the P4-P6 domain, the YSGX library failed to produce 
RNA-binding Fabs for a variety of RNA targets (75). The YSGRX library does produce RNA-
binding Fabs for many RNA targets, however, often their affinity and specificity are relatively 
low, requiring affinity-maturation before the Fabs can be used effectively in downstream 
biochemical experiments (75). For instance, the best Fab selected directly from the YSGRX 
library binds the class I ligase with an affinity of 338 nM. It was affinity-matured to an affinity of 
35 nM through error-prone PCR Fab library production followed by additional rounds of 
selection before it was used to co-crystallize the class I ligase (75). 
Here we describe the design, construction, selection, and characterization of a new Fab 
library designed specifically for RNA recognition. We aimed to create an antibody library with a 
large randomized surface area and a chemical diversity tailored for RNA-binding. Because 
libraries with strictly limited chemical diversity are functional (87, 90-92) and they allow the 
sampling of a larger sequence space than libraries more chemically diverse, we produced an 
antibody library, YSGR Min library, with strictly limited chemical diversity to Tyr, Ser, Gly, and 
Arg amino acids spread out on all six CDR loops. Our results showed that although the amino 
acid composition is extremely limited, the YSGR Min library produced Fabs successfully for all 
three RNA targets used in selection, and their affinities and specificities are comparable to or 
slightly better than those from the YSGX and YSGRX library which employs a much richer 
amino acid composition. This library will serve as a basis for supplementing and testing the 
effect of additional amino acids for future library improvement. 
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3.2 Results 
 
3.2.1 Design of the RNA-targeting Fab library with a minimal amino acid composition 
 
Our immediate goal is to search for and test the Fab variable sites that are suitable for 
RNA recognition. As the YSGX and YSGRX libraries, combined together, have reasonable 
successes in RNA recognition (74, 75), they naturally become a good starting point for the new 
library. In both YSGX and YSGRX libraries, only solvent exposed residues in four out of si x 
complementarity determining regions (CDRs) were randomized, including CDR-L3, CDR-H1, 
CDR-H2, and CDR-H3, while CDR-L1 and CDR-L2 were held constant (74, 75, 87). Similar to 
that in the YSGX and YSGRX libraries, a total of 15 solvent exposed sites were chosen as 
variable sites in CDR-L3, CDR-H1, and CDR-H2 for our minimal library. Solvent exposed 
positions in CDR-H3 were replaced by random-sequence loops of three different lengths. In 
addition, six structurally important residues (framework residues) in these CDRs were given a 
small subset of variability as designed in both YSGX and YSGRX libraries (74, 75, 87). Two 
framework residues, heavy chain Ile34 (located in CDR-H1) and Gly55 (CDR-H2), were 
completely fixed in the YSGR Min library as they are almost fully conserved in P4-P6 and ligase 
I binding Fabs (74, 75) and other RNA-binding Fabs (unpublished results). 
In the Fab-RNA binding interface, we found CDR-L1 and CDR-L2 play an important role 
in RNA recognition (74), suggesting that including CDR-L1 and CDR-L2 in the randomization 
may improve RNA binding efficiency in the library. We examined all the residues in CDR-L1 and 
L2 defined by the Kabat definition (93) and their flanking regions in the crystal structure of Fab2-
P4-P6 with PyMOL software (The PyMOL Molecular Graphics System, Version 0.99rc6, 
Schrödinger, LLC). Solvent exposed and potential contact residues were identified as positions 
28-32 in CDR-L1 and positions 49-50, 52-53, 55-56, and 60-61 in CDR-L2.  
Adding all the variable sites from six CDRs gives a total of 37 randomized locations in 
the library design, which correspond to a theoretical library size of 4.9 x 1055 if we use NNK (N = 
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A, C, G, or T; K = G or T) to encode for all 20 amino acids types at each variable site. This is 
drastically larger than the practical size (~ 1010-11) of a typical phage displayed library achievable 
in the laboratory and the large gap reduces the effectiveness of the constructed library (92). To 
decrease the size gap and increase the potency of the library, we will adopt the reduced 
chemical diversity design in which variable sites are randomized with only a small fraction of the 
natural spectrum of the amino acids. This reduced chemical diversity design has been 
successfully employed in the Fab libraries for protein targets using either highly frequent amino 
acids from the Kabat database (88, 94) or in two extreme cases, a tetranomial code (Tyr, Ala, 
Asp, Ser) (90) and a binomial code (Tyr and Serine) (91). 
Inspired by the success of the reduced chemical diversity and minimal diversity in the 
Fab libraries for protein targets, we have decided to use an extremely simplified amino acid 
composition for our library. This library design tests the minimal requirements of Fab-RNA 
binding interfaces. One advantage of this extremely simplified library is that if it is reasonably 
effective, it can serve as a basis to introduce and test more amino acid composition in future 
library designs. We chose a tetranomial code (Tyr, Ser, Gly, Arg) in the design of our library, 
named YSGR Min. Tyr and Ser were chosen as they are the most abundant amino acids in the 
selected RNA-binding Fabs binding to the P4-P6 domain (74), the class I ligase (75), and other 
RNA targets (J. Y., unpublished results). Gly was chosen because it is known to be flexible and 
advantageous in the CDR loops to achieve many efficacious conformations for antigen binding 
(92); indeed, it is relatively abundant in the Fab-RNA interfaces (74, 75). Both Arg and Lys were 
abundant in the Fab-RNA interfaces as well as other protein-RNA interfaces (95, 96), however, 
only Arg was chosen because the longer and more flexible Lys may be less beneficial (bulky) to 
the antigen binding interfaces. 
3.2.2 Construction of the YSGR Min library 
 
The YSGR Min library was constructed from a single Fab framework (P4-P6 binding 
Fab2) using Kunkel mutagenesis (97). As Kunkel mutagenesis generally retains a significant 
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amount of the unmutated template gene, to prevent the overpopulation of the parent Fab in the 
library, we first generated a DNA clone with two TAA stop codons added in all six CDR regions 
from P4-P6 binding Fab2 using Kunkel mutagenesis. After verifying stop codon insertion in all 
CDRs via sequencing, we made the single-stranded DNA (ssDNA) of this stop template clone 
and used it as the template for library construction (Figure 3.1). 
 
Figure 3.1 Construction of the YSGR Min phage displayed antibody library through 
oligonucleotide-directed mutagenesis.  
 
Sixteen synthetic oligonucleotide primers (two for each of CDR-L1, L2, L3, H1, H2, and six for 
CDR-H3) are annealed to the dU-ssDNA template (dashed circle). These oligonucleotides 
contain mutations that encode the library diversities which are flanked by perfectly 
complementary sequences. Chemical diversities (Y/S/G/R) are encoded by two alternating 
degenerate codons (TMT for Y/S and VGT for S/G/R) in pairs of Kunkel primers. Heteroduplex 
dsDNA is enzymatically synthesized by T7 DNA polymerase and T4 DNA ligase, then 
transformed into E. coli SS320 or XL1-blue cell hosts where the dU-ssDNA is converted into T-
containing DNA that is fully complementary to the mutant sequence (circle with solid line). 
 
The designed diversity (YSGR) was incorporated into the Fab genes through 
oligonucleotide primers similarly via Kunkel mutagenesis (98). For synthetic ease and 
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economical reasons, we employed the degenerate codon method to establish sequence 
diversity in the primer design. However, there is no single degenerate codon encoding all four 
YSGR residues without introducing detrimental extra codons such as cysteines and stop 
codons. To exclude these from our design, we utilized two separate degenerate codons, TMT 
(M = A or C) to encode equal portions of Tyr and Ser, and VGT (V = A, C, or G) to encode equal 
portions of Ser, Gly, and Arg. These two codons were applied in an alternating fashion in the 
randomized CDR sequence, and furthermore, oligonucleotide primer pairs were used to apply 
TMT and VGT codons to both odd and even numbered positions. For example, for positions 28-
32 of CDR-L1, primers containing either TMTVGTTMTVGTTMT or VGTTMTVGTTMTVGT were 
used in the library construction. This alternating approach has a serendipitous advantage in that 
it eliminates consecutive arginines. This is advantageous because Fabs produced by the 
YSGRX library frequently contain consecutive Arg in CDR-H3, which often increase non-specific 
binding to RNAs (75). 
For the most flexible and important CDR-H3, we have designed three different lengths 
for the peptide chain sequence to increase the effectiveness of the library. This increased the 
total number of primers to an unprecedented 16 in a one-pot Kunkel reaction. Our initial attempt 
in the Kunkel reaction resulted in low yield in the desired product. Reaction optimizations for 
annealing procedure, primer-to-template ratio, enzyme concentration, and incubation 
temperature and duration were carried out to maximize the reaction yield. In the optimized 
annealing procedure, we mixed all sixteen phosphorylated primers with single-stranded DNA 
template (total primer concentration at a given CDR location/template concentration = 3) and 
incubated the mixture at 95 oC for 2 min, 50 oC for 3 min and then room temperature for 5 min. 
After annealing, ATP, dNTP, DTT, T4 DNA ligase, and T7 DNA polymerase were added 
sequentially and the mixture was incubated at room temperature overnight. After the 
polymerization and ligation step, the reaction mixture was purified and electroporated into 
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electrocompetent SS320 cells to obtain the YSGR Min library (99) with an apparent diversity of 
3.2 x 109. This library was then used in the following selection and characterization (Figure 3.2). 
 
Figure 3.2 RNA-binding Fab selection, expression, and application.  
 
A library of bacteriophage displaying Fabs were allowed to bind biotinylated RNA target 
complex immobilized on the streptavidin-coded magnetic beads. After washing, specific binders 
were selectively eluted by degradation of the RNA target with RNase A. Individual clones can be 
screened by phage Enzyme-Linked Immunosorbent Assay (ELISA) with biotinylated RNA target 
complex immobilized on neutravidin-coated Maxisorp plates. Positive clones can be sequenced, 
expressed, and purified to generate soluble Fabs. These specific Fabs are characterized to 
verify desired binding affinity and specificity and used in basic biochemical research or 
therapeutic drug development targeting structured RNAs. 
 
3.2.3 Selection of the YSGR Min library against three RNA targets 
 
After the YSGR Min Fab library was constructed, it was screened against three RNA 
targets: the P4-P6 domain (P4-P6)(74, 100), the Fusobacterium nucleatum glycine riboswitch 
(FNI-II)(13, 51), and the Vibrio cholerae glycine riboswitch (VCI-II)(6). The P4-P6 domain is an 
individual structural domain of the self-splicing Tetrahymena Group I intron and folds into a well-
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defined three-dimensional structure. FNI-II is a cis-acting non-coding RNA that switches its 
structure upon binding glycine molecules and controls downstream gene expression in 
Fusobacterium nucleatum. FNI-II folds into a compact three-dimensional structure and its crystal 
structure was determined by the Strobel lab (19). VCI-II is similar to FNI-II in its function; 
however, it is significantly larger with several extra domains and does not yet have a crystal 
structure. For P4-P6 and VCI-II, we have selected Fabs from the YSGX or YSGRX libraries (42, 
74), which will allow us to compare the affinities and specificities of these Fabs to those 
obtained from the YSGR Min library. 
In order to immobilize the RNA targets for selection (Figure 3.2), we extended the 3’ end 
of all three RNA targets with a 29 nucleotide tag sequence to prepare the corresponding RNA 
targets for selection: P4-P6Tag, FNI-IITag, and VCI-IITag. These RNA targets were then 
annealed with 5’ biotinylated DNA, allowing immobilization onto streptavidin coated magnetic 
beads for selection (74). In the first round, the biotinylated DNA annealed RNA targets were 
immobilized on the streptavidin coated magnetic beads before binding to the YSGR Min library 
in the presence of RNase inhibitor. After brief washing steps, the phage bead complex was 
directly used to infect XL1-blue cells for reamplification for future rounds of selection. In the 
second round, purified phage pools were first incubated with streptavidin beads to remove the 
streptavidin binders and the supernatant was then used to bind biotinylated DNA annealed RNA 
targets (50 nM) in the presence of 50 µg/ml E. coli tRNA mixture and RNase inhibitor before 
being mixed with and captured on fresh aliquot of streptavidin beads. After extensive washing 
steps, biotinylated RNase A was used to selectively elute the RNA binding phage, which was re-
amplified and purified for future rounds. In the third round and later rounds, selection was 
carried out similar to the second round except that RNA target concentration was at 5 nM and 
the E. coli tRNA competitor concentration was 500 µg/ml, which was used as a stringent 
condition to increase the affinity and specificity of the selected Fabs. In the second and later 
rounds, selection was carried out in parallel with a control experiment in which no RNA target 
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was present. The number of phage in the input, output, and control experiments were titered on 
the LB ampicillin plates. The enrichment number was calculated as output phage numbers in 
the target selection divided by that in the non-target control experiment, and the reduction ratio 
was calculated as the ratio of input phage number divided by the output phage number in the 
control experiment. These two selection parameters were used to monitor the selection process 
and summarized in Table 3.1. As the selection proceeds, the enrichment gradually increases, 
reaching about two orders of magnitude when the selection was stopped. The background 
reduction ratio remained relatively constant, indicating credible enrichment numbers. No more 
than five rounds were needed for each RNA target, showing the effectiveness of the YSGR Min 
library. 
Table 3.1 Phage display selection results of YSGR Min library against RNA targets. 
RNA targetsa Round # Enrichment Reduction Rate 
P4-P6 
2 11.87 7.01x105 
3 269.67 4.66 x106 
 
 
  
FNI-II 
2 .77 2.6x107 
3 8.12 3.54x107 
4 34.42 9.06x104 
5 75.6 2.62x104 
    
VCI-II 
2 1.61 8.89x105 
3 6.84 3.11x107 
4 176.97 9.27x104 
a P4-P6: ∆C209 P4-P6 domain from Tetrahymena Group I intron. FNI-II: the glycine riboswitch 
from Fusobacterium nucleatum. VCI-II: the glycine riboswitch from Vibrio cholerae. 
 
3.2.4 Screening individual phage clones by Enzyme-Linked Immunosorbent Assay (ELISA) 
 
After successful phage selection, individual phage clones were screened against RNA 
targets by Enzyme-Linked Immunosorbent Assay (ELISA, Figure 3.2). We adapted the phage 
ELISA procedure published by Sidhu et al. to be suitable for RNA binding phage displayed Fab 
screening (98). The phage ELISA screening was performed in 96 well Maxisorp immunoplates. 
To ensure the RNA targets are intact and correctly folded, instead of directly immobilizing the 
targets on the plate as for protein targets, we immobilized the neutravidin first on the Maxisorp 
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plate and then bound the biotinylated DNA annealed RNA targets to the neutravidin on the 
plate. Phage solutions grown from individual clones were then added to the RNA bound wells as 
well as neutravidin coated control wells in the presence of vanadyl ribonucleotide complex and 
sheared salmon DNA. Here vanadyl ribonucleotide complex is used as an inexpensive 
substitute for RNase inhibitor and the sheared salmon DNA is used as a nucleic acid 
competitor. After washing steps, the plate bound phage were then recognized by anti-M13 
antibody/horseradish peroxidase conjugate, detected by 3,3',5,5'-tetramethylbenzidine (TMB) 
solution, quenched by phosphoric acid to give yellow color, and quantified 
spectrophotometrically by a microtiter plate reader. A high ratio between the target well and the 
control well indicates positive, specific binding of the RNA targets. Ten positive clones for each 
of the three targets were sent for sequencing. The sequences of the unique clones are shown in 
Table 3.2. For target P4-P6, besides obtaining a sequence as designed in the library (Fab8), we 
also obtained the parent Fab2 and a partially mutated Fab11. We attribute this to a trace 
amount of contamination of Fab2 in the stop template clone which was not detected by 
sequencing. For FNI-II and VCI-II targets, we obtained multiple unique sequences which were 
all as designed in the library. 
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Table 3.2 Sequences and affinities of the selected Fabsa. 
RNA 
Targets 
Fab 
Clones
b CDR-L1 CDR-L2 CDR-L3 CDR-H1 CDR-H2 CDR-H3 Kd (nM) 
P4-P6 
 
2 (6)
c 
SVSSA YSASSLYSGVPSR SYSSPI NLYSSSI YISSSYGYTY RAAGMSTY-GF 66±13 
8 (1) YGYRS YSASGLYRGVPSR GYRSPV NLGSGYI SYRPSSGSTR SYSSRYSY-AM 54±2 
11 (3) SVSSA YSASSLYSGVPSR SYSSPI NLYSSSI SRSPRSGGTS RAAGMSTY-GF 22±3 
        
 
FNI-II 
10 (2) GYSYS YGAYRLSRGVPYG YSSGPV NISYGSI SSYSRYGRTY SRSRSSY--AM 1.5µM 
12 (1) SRYRY RSASSLSSGVPSY YSYRLI NIGSRSI SGSSRYGGTY 
SGSGSSSRYG
M 
nd
d 
14 (1) YGSGY SGASGLSGGVPSG SYRYPF NVSGSRI SGSSGYGGTS SRSRYSYRYGL 1.5µM 
15 (2) GYSYS YGAYRLYGGVPSR SSRSLV NISSYSI SRSPRSGRTS YRYRSGS--GL 600±180 
16 (2) YSSRY YGAYGLYRGVPYR SYSYPI NLGYRYI SGSSGSGSTY GSSYSYRY-AF 160±12 
18 (1) GYGSR YSASRLSRGVPSS YSYSLL NFSSGYI YGSPSSGRTS SSYRSRYG-AM 2.0µM 
        
 
VCI-II 
24 (1) YRYRS SGAYGLYRGVPSR YRSGLV NVSSSSI GSRSSSGSTG SSYGSRSS-AM 1.5µM 
25 (2) YRYRS SGAYSLYRGVPYR YSSGLI NFSSGSI GSGPSRGSTS SRSRSRSR-AM 333±110 
27 (2) SGSRS YGASSLYGGVPSR YSYGLL NFRSRYI 
GSGPSRGYT
G 
GSRYRYGSRG
M 
559±208 
29 (2) YSYRS YRASRLYGGVPSR RSSYPV NFSGSSI YGSPGYGRTS 
SSYGSRSGYA
M 
39±2 
30 (1) SGSSY YRASSLSSGVPSR YSSRLL NIYRYGI YGSPGSGRTY RYRYRYRS-GL 22±1 
31 (1) RYRSG SGAYGLYSGVPSR YGSGLI NFRYRSI SRSSRSGRTS SRSGYSSG-AL 408±139 
a Tyr, Ser, Gly, and Arg residues are shaded in yellow, red, green, and pink, respectively. 
Unmutated residues are shaded in grey. Framework residues with limited randomization are 
unshaded. Dashes indicate gaps in the alignment. 
b Numbers in parentheses indicate the frequency of the Fab sequences from the 10 sequenced 
clones for each target. 
c This Fab is identical to the parent Fab. 
d Binding is not detected. 
 
3.2.5 Expression and characterization of the Fabs 
 
Phage ELISA identifies positive Fab clones binding to stationary RNA targets, which 
may be complicated by Fab-phage fusion or the expression level of Fabs, making it difficult to 
obtain accurate measurements of the binding affinities and specificities. To overcome these 
difficulties, unique clones identified by phage ELISA and sequencing were expressed as soluble 
Fabs for further biochemical characterization (42). Stop codon (TAG) was introduced to the 
phagemid through Kunkel mutagenesis to break the fusion between Fab gene and protein III, a 
coat protein of the M13 phage. The clones carrying the TAG mutation were identified by colony 
PCR. These resulting expression clones were transformed into E. coli 34B8 strain for 
expression followed by purification on protein A affinity column with published protocols (42).  
We first used the Electrophoretic Mobility Shift Assay (EMSA) on native gel to analyze 
the binding between P4-P6 and its selected Fabs (Figure 3.3A). Results showed that both Fab8 
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and Fab11 form a discrete and slower-migrating complex with P4-P6 similar to the parent Fab2, 
suggesting that they may bind P4-P6 with high affinities and specificities. As glycine is needed 
to keep VCI-II and FNI-II in their native folding states, to analyze the binding between the 
glycine riboswitch binding Fabs, we used an analogous modified native gel assay, termed 
Polyacrylamide Coelectrophoresis (PACE) in which a saturating amount of glycine was added in 
the polyacrylamide gel to maintain glycine riboswitch structure. Results showed that Fab16 
forms a discrete complex with FNI-II glycine riboswitch (Figure 3.3B) and Fab29 and Fab30 
form a discrete complex with VCI-II glycine riboswitch (Figure 3.3C), indicating these Fabs may 
bind their targets with high affinities and specificities. However, multiple Fabs selected against 
VCI-II and FNI-II glycine riboswitches do not form a discrete complex under gel electrophoresis, 
indicating they are either weak binders or non-specific binders. 
 
Figure 3.3 Gel images of native electrophoretic mobility shift assay (EMSA) and polyacrylamide 
coelectrophoresis.  
 
A) Fabs binding to P4-P6. Lane 1, P4-P6 only; Lanes 2-4, 2 µM of P4-P6 with 1.6 µM of Fab8, 
Fab2, and Fab11, respectively. B) Fabs binding to FNI-II. Lane 1, FNI-II only; Lanes 2-7, 2 µM 
of FNI-II with 2 µM of Fab10, Fab12, Fab14, Fab15, Fab16, and Fab18, respectively. C) Fabs 
binding to VCI-II. Lane 1, VCI-II only; Lanes 2-7, 2 µM of VCI-II with 2 µM of Fab24, Fab25, 
Fab27, Fab29, Fab30, and Fab31, respectively. 
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We next employed filter binding assays to determine dissociation constants (Kds) for 
binding between Fabs and their 32P-labelled RNA targets. Results showed that both Fab8 and 
Fab11 bind P4-P6 with high affinities, 54 nM and 20 nM (Figure 3.4A, Table 3.2), respectively, 
comparable to or slightly better than the parent Fab2 with an affinity of 66 nM. Out of six Fabs 
selected for FNI-II glycine riboswitch, one Fab (Fab12) did not show detectable binding; three 
Fabs (Fab10, Fab14 and Fab18) showed binding affinities larger than 1 µM; one Fab (Fab15) 
showed binding affinity in the high nanomolar range. These results are consistent with the 
native gel results in which they do not form a discrete and slower-migrating complex with FNI-II. 
In contrast, Fab16 binds FNI-II with midnanomolar affinity (160 nM, Figure 3.4B, Table 3.2), 
consistent with complex formation in the native gel assay. For VCI-II glycine riboswitch target, 
one Fab (Fab24) showed a binding affinity lower than 1 µM and three Fabs (Fab25, Fab27 and 
Fab31) showed binding affinities in the high nanomolar range, consistent with the lack of 
complex formation in the native gel assay. However, as the native gel results predicted, Fab29 
and Fab30 bind VCI-II glycine riboswitch with high affinities, 39 nM and 22 nM, respectively 
(Figure 3.4C, Table 3.2). 
Combining the results of the native gel shift assay and the filter binding assay, the YSGR 
Min library has successfully produced at least one Fab for each of the three RNA targets that 
shows tight binding affinity and forms a specific complex with its target. 
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Figure 3.4 Binding curves for the selected Fabs with their cognate RNA targets, P4-P6 (A), FNI-
II (B), and VCI-II (C).  
 
Fabs that form discrete bands with their cognate RNAs on native gel are represented by solid 
symbols; others use open symbols. These fraction binding data are not normalized for direct 
comparison to the raw binding data in the specific binding assay reported in Table 3.3. 
3.2.6 Specificity Assay 
 
An antibody library designed for RNA targets could be potentially very useful for RNA 
crystallization, oncogenic RNA recognition and neutralization, and other biochemical 
applications. However, the nature of the molecular recognition requires the Fab obtained from 
the library to be not only a tight binding one, but also highly specific as well. Our native gel shift 
assay and filter binding assay showed that we have obtained tight-binding Fabs for all three 
RNA targets from the YSGR Min library. However, the specificity of these Fabs is not rigorously 
assessed. Currently there is no quantitative way for measuring the specificity of an RNA-binding 
Fab. We have now designed a competitive filter binding assay for this purpose.  
In the competitive filter binding assay, a reference point is first determined which 
measures the percent binding of the 32P labeled cognate RNA to Fab at Fab concentration of 
2Kd. Here Fab concentration of 2Kd is chosen instead of Kd to ensure a detectable percent 
binding value as Fabs with low specificity or low affinity often lead to unexpectedly low binding 
values possibly due to low accuracy in the determination of the binding affinity. By definition, this 
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reference point should be around 67% of the maximum fraction of binding (unnormalized), 
empirically high enough to give a consistent signal. Next, similar percent binding data was 
obtained with the competition of each of the seven non-radiolabeled non-cognate RNAs present 
at a concentration equal to 2Kd. The percent binding values obtained with seven competitors 
were then averaged, divided by the reference point, and averaged over two independent 
experiments to give Fab Specificity Index (FSI) for a given Fab target pair (Table 3.3). This FSI 
value ranges from 0 to 1, with 0 indicating completely non-specific and 1 indicating extremely 
specific within the choice of competitive RNAs. 
Table 3.3 Specificity binding raw data and Fab specificity index values. 
Targets
a Fab 
Clones 
Competitive RNAs
a
 
FSI
b
 
P4-P6 FNI-II VCI-II ExD1 AMTHF DASAH tRNA CBATHF 
P4-P6 
2 
0.386
c
 0.363 0.375 0.310 0.341 0.320 0.325 0.321 
0.888 
0.364 0.333 0.323 0.328 0.343 0.335 0.315 0.324 
8 
0.479 0.466 0.474 0.441 0.452 0.366 0.388 0.403 
0.926 
0.449 0.453 0.463 0.412 0.442 0.424 0.447 0.382 
11 
0.501 0.396 0.456 0.407 0.420 0.399 0.369 0.387 
0.821 
0.476 0.407 0.409 0.430 0.434 0.411 0.378 0.315 
FNI-II 
15 
0.352 0.570 0.249 0.0966 0.223 0.208 0.189 0.336 
0.371 
0.397 0.704 0.260 0.0873 0.183 0.163 0.179 0.344 
16 
0.671 0.539 0.780 0.514 0.563 0.513 0.484 0.560 
1.045 
0.654 0.549 0.679 0.529 0.605 0.505 0.434 0.462 
VCI-II 
25 
0.123 0.0586 0.355 0.0169 0.0620 0.0563 0.0937 0.0844 
0.255 
0.203 0.134 0.423 0.0916 0.154 0.0977 0.155 0.0861 
27 
0.168 0.0922 0.210 0.0419 0.0936 0.0899 0.119 0.139 
0.424 
0.163 0.101 0.312 0.0572 0.113 0.0789 0.114 0.118 
29 
0.348 0.305 0.338 0.343 0.336 0.297 0.282 0.266 
0.972 
0.402 0.409 0.362 0.323 0.405 0.327 0.354 0.374 
30 
0.297 0.232 0.221 0.231 0.0860 0.229 0.216 0.212 
0.933 
0.234 0.265 0.248 0.208 0.192 0.212 0.232 0.209 
31 
0.259 0.192 0.290 0.135 0.187 0.159 0.199 0.254 
0.683 
0.376 0.277 0.396 0.214 0.269 0.248 0.274 0.245 
18 
0.418 0.293 0.442 0.228 0.261 0.253 0.249 0.265 
0.683 
0.469 0.315 0.453 0.289 0.416 0.257 0.294 0.278 
20 
0.0583 0.0987 0.138 0.0375 0.101 0.0718 0.154 0.0733 
0.622 
0.0541 0.112 0.132 0.0407 0.0807 0.0823 0.143 0.0674 
a P4-P6, FNI-II, and VCI-II are the same as described in Table 3.1. ExD1: exD1 domain from 
ai5  Group II intron. AMTHF: Alkaliphilus metalliredigens tetrahydrofolate riboswitch. DASAH: 
Dechloromonas aromatica SAH riboswitch. tRNA: E coli tRNA mixture. CBATHF: the 
tetrahydrofolate riboswitch from Clostridium botulinum A. 
b FSI, Fab Specificity Index. For a given pair of Fab and RNA target, FSI value = (sum of 
unshaded raw data/7)/(shaded reference data) for each replicate. The two replicates are then 
averaged to produce the given value. 
c Shaded data: reference point, no competitive RNA was added. 
 
80 
 
Table 3.3 shows the results of the competitive filter binding assay of the selected Fabs. 
The reference point of the Fabs for P4-P6 is very close to 67% of the maximum fraction of 
binding as expected (Table 3.3, Figure 3.4A). For instance, the maximum fraction of Fab8 
binding to P4-P6 is around 0.61 (Figure 3.4A), the reference point of ~0.45 corresponds to 74% 
of the maximum fraction binding, close to 67% expected. With the addition of competitive RNAs, 
the percent binding values were only reduced marginally for all seven competitor RNAs. The 
FSI values of both Fab8 and Fab11 are close to one, comparable to the value of Fab2, a Fab 
that was co-crystallized with P4-P6 previously, confirming their high binding specificities.  
Two FNI-II binding Fabs (Fab15 and Fab16) have affinities better than 1 µM and their 
binding specificity values were determined. With the addition of competitive RNAs, the changes 
in the percent binding values are very different for these two Fabs (Figure 3.4B). For Fab16, the 
percent binding values barely changed compared to its reference point while the values for 
Fab15 were reduced significantly. The FSI values for Fab16 and Fab15 are 1.05, and 0.37, 
respectively, indicating that Fab16 is highly specific while Fab15 is not, consistent with our 
native gel shift assays. 
Five of the VCI-II glycine riboswitch binding Fabs with affinities better than 1 µM were 
analyzed by the competitive filter binding assays. Results showed that Fab25 and Fab27 have 
low specificities, with FSI values of 0.26 and 0.42, respectively. Fab31 has a medium FSI value 
of 0.68, indicating Fab31 as a reasonably specific Fab. Perhaps the lack of a specific complex 
formation of Fab31 with VCI-II in the native gel experiment is due to its low binding affinity. On 
the other hand, both Fab29 and Fab30 are highly specific with FSI values close to one. We 
have also measured the FSI values of Fab18 and Fab20, which were selected against VCI-II 
from the YSGRX library (42). Results showed that Fab18 and Fab20 have medium specificities 
with FSI values of 0.68 and 0.62, respectively. These values are significantly lower than that of 
Fab29 and Fab30, indicating that the YSGR Min library can produce exceptionally specific RNA-
binding Fabs, even better than the YSGRX library. As both Fab18 and Fab20 have consecutive 
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arginines in CDR-H3 while Fab29 and Fab30 do not (42), these higher specificity values of 
Fab29 and Fab30 may indicate the success of the alternating codon design in avoiding 
consecutive arginine stretches in the Fab CDRs of the YSGR Min library. 
3.3 Discussion 
 
In this work, we have constructed the YSGR Min library with minimal chemical diversity 
in an antibody Fab framework. Compared to previous Fab libraries (YSGX and YSGRX 
libraries) that have been tentatively used for RNA targets, the YSGR Min library is uniquely 
different in the following aspects: 1) the YSGR Min library expands the variable sites to include 
all six CDRs versus only four CDRs in the other two libraries; 2) the chemical diversity of the 
YSGR Min library is restricted to include only Tyr, Ser, Gly and Arg; 3) the minimal YSGR 
chemical diversity is applied to all six CDRs while the YSGX and YSGRX libraries use binary 
code (Tyr and Ser only) for CDR-L3, H1 and H2, and 19 amino acid types (no Cys) for CDR-H3; 
4) the alternating codon design eliminates the consecutive arginines in the CDRs while the 
YSGRX library frequently produced stretches of consecutive arginines in CDR-H3. The YSGR 
Min library was selected against three RNA targets and has yielded high-affinity and high-
specificity Fabs for each of them. This suggests that the minimal chemical diversity is sufficient 
to make tight and specific contact with RNA targets, different from a much broader amino acid 
spectrum used in common RNA binding protein interfaces (95, 96, 101, 102). These findings 
may provide a unique approach to designing future RNA-binding proteins. Using a competitive 
filter binding assay, we have defined the specificity of the high-affinity RNA binding Fabs and 
found that these Fabs have higher specificity compared with the Fabs selected from the YSGRX 
library. This correlates well with the lack of consecutive arginine stretches in the CDR and 
suggests the superiority of the alternating codon design over the uniform codon design. The 
detrimental effect of a large amount of arginines at the Fab-antigen interface is also consistent 
with the findings of Birtalan et al. (103), in which the authors reported that arginine content 
clearly correlates with the increased non-specific binding between synthetic Fabs and protein 
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antigens. High specificity is very important to achieve high homogeneity in complex formation 
with the high sample concentrations used in crystal screening. This may partially explain the 
difficulty in obtaining crystal formation using Fab18 and Fab20 in co-crystallizing VC glycine 
riboswitch (J. Y., unpublished results). High specificity is also very important for future 
diagnostic tool or drug design targeting oncogenic RNAs, where off-target effects generally are 
detrimental. We have noticed that besides the high-affinity and high-specificity Fabs obtained for 
each target, we have also obtained weak binding and low specificity Fabs for two of the targets. 
We suspect that this is due to oversimplified codon design. With the current YSGR minimal 
codon design as a working basis, additional amino acids can be supplemented and tested for 
their effect on RNA binding affinity and specificity.  
3.4 Materials and Methods 
 
3.4.1 DNA constructs of the RNAs 
  
 The Fusobacterium nucleatum glycine riboswitch (FNI-II), Vibrio cholerae glycine 
riboswitch (VCI-II), Alkaliphilus metalliredigens tetrahydrofolate riboswitch (AMTHF), Clostridium 
botulinum A tetrahydrofolate riboswitch (CBATHF) and Dechloromonas aromatica SAH 
riboswitch (DASAH) genes (104) were generated by recursive PCR (55, 105) from DNA 
oligonucleotides (Integrated DNA Technologies) with EcoRI restriction site engineered at the 5’ 
and EarI and HindIII sites at the 3’ (6, 13). For RNAs used as Fab selection targets, an extra 29 
nucleotide tag (GCTTTAGGTCGACTCTAGAGGATCCCCGG) was added to the 3' of the gene 
during recursive PCR. RNA genes and pUC19 vector were double digested with both EcoRI and 
HindIII restriction enzymes and ligated together with T4 DNA ligase to generate plasmids pVCI-
II and pFNI-II according to standard protocols (42). These plasmids and plasmids containing 
Tetrahymena ∆C209 P4-P6 group I intron domain(100) and ai5  exD1 group II intron domain 
(106) were transformed in JM109 cells, amplified, and linearized by EarI restriction enzyme to 
generate transcription templates. 
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3.4.2 In vitro transcription for the preparation of RNAs 
 
 RNAs were transcribed in 40 mM Tris-HCl (pH 7.9), 2 mM spermidine-3HCl, 10 mM 
DTT, 25 mM MgCl2, and 5 mM each of the nucleotide triphosphates for 4 h at 37°C. All the 
RNAs were purified by 6% polyacrylamide gel electrophoresis, isolated with UV shadowing and 
excised, electroeluted into TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA), PCA extracted, 
ethanol precipitated, and resuspended in TE buffer. RNA concentrations were determined by 
UV absorbance at 260 nm wavelength. E coli tRNA mixture purchased from Sigma-Aldrich was 
used directly as a competitor in the competitive filter binding assay without purification. 
3.4.3 Preparation of the stop template for library construction 
 
 The phagemid of P4-P6 Fab2, designed to display bivalent, humanized Fab on the 
surface of M13 bacteriophage has been described previously (42). Electroporation of this 
phagemid into CJ236 cells (uracil deglycosidase deficient) generated uracil-containing ssDNA 
by following the procedure as described (42). The following Kunkel primers were designed to 
insert two stop codons (underlined) into each of the six CDRs through Kunkel mutagenesis: (97) 
ACCTGCCGTGCCAGTCAGTAAGGCCAAGACGGCCTATAAGTAGCCTGGTATCAACAG 
(CDR-L1), 
GCTCCGAAGCTTCTGATTTAAGGCCAAGACGGCCTATAATTCTCTGGTAGCCGTTCC 
(CDR-L2), 
ACTTATTACTGTCAGCAATAAGGCCAAGACGGCCTATAAACGTTCGGACAGGGTACC 
(CDR-L3), 
GCAGCTTCTGGCTTCAACTAAGGCCAAGACGGCCTATAACACTGGGTGCGTCAGGCC 
(CDR-H1), 
GGCCTGGAATGGGTTGCATAAGGCCAAGACGGCCTATAATATGCCGATAGCGTCAAG 
(CDR-H2), 
GTCTATTATTGTGCTCGCTAAGGCCAAGACGGCCTATAAGACTACTGGGGTCAAGGA 
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(CDR-H3). After phosphorylation using T4 Polynucleotide kinase, these primers were annealed 
with uracil-containing ssDNA of P4-P6 Fab2, extended with T7 DNA polymerase, ligated with T4 
DNA ligase, and transformed into XL1-blue cells  (uracil glycosidase containing strain) to 
generate a phagemid encoding Fab stop template (pFyes1) following the procedure as 
described (42). Small scale DNA was purified using Qiagen’s miniprep kit and sent for 
sequencing to confirm the sequence (Eton Bioscience Inc.). 
3.4.4 Construction of the YSGR Min library 
 
 Single-stranded DNA encoding Fab stop template (pFyes1) was prepared similar to the 
procedure described above. The following 16 Kunkel primers were designed to incorporate 
designed diversity (underlined, where M = A or C; V = A, C, or G) into all six CDRs through 
large scale Kunkel mutagenesis: (97, 98) 
ACCTGCCGTGCCAGTCAGTMTVGTTMTVGTTMTGTAGCCTGGTATCAACAG (CDR-L1), 
ACCTGCCGTGCCAGTCAGVGTTMTVGTTMTVGTGTAGCCTGGTATCAACAG (CDR-L1), 
GCTCCGAAGCTTCTGATTVGTTMTGCAVGTTMTCTCVGTTMTGGAGTCCCTVGTTMTTTCT
CTGGTAGCCGTTCC (CDR-L2), 
GCTCCGAAGCTTCTGATTTMTVGTGCATMTVGTCTCTMTVGTGGAGTCCCTTMTVGTTTCT
CTGGTAGCCGTTCC (CDR-L2), 
ACTTATTACTGTCAGCAATMTVGTTMTVGTCYGNTTACGTTCGGACAGGGTACC (CDR-L3), 
ACTTATTACTGTCAGCAAVGTTMTVGTTMTCYGNTTACGTTCGGACAGGGTACC (CDR-L3), 
GCAGCTTCTGGCTTCAACNTTTMTVGTTMTVGTATTCACTGGGTGCGTCAGGCC (CDR-H1), 
GCAGCTTCTGGCTTCAACNTTVGTTMTVGTTMTATTCACTGGGTGCGTCAGGCC (CDR-H1), 
GGCCTGGAATGGGTTGCAVGTTMTVGTYCTTMTVGTGGCTMTACTVGTTATGCCGATAGC
GTCAAG (CDR-H2), 
GGCCTGGAATGGGTTGCATMTVGTTMTYCTVGTTMTGGCVGTACTTMTTATGCCGATAGC
GTCAAG (CDR-H2), 
GTCTATTATTGTGCTCGCVGTTMTVGTTMTVGTTMTVGTGSTWTKGACTACTGGGGTCAAG
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GA (CDR-H3), 
GTCTATTATTGTGCTCGCTMTVGTTMTVGTTMTVGTTMTGSTWTKGACTACTGGGGTCAAG
GA (CDR-H3), 
GTCTATTATTGTGCTCGCVGTTMTVGTTMTVGTTMTVGTTMTGSTWTKGACTACTGGGGTC
AAGGA (CDR-H3), 
GTCTATTATTGTGCTCGCTMTVGTTMTVGTTMTVGTTMTVGTGSTWTKGACTACTGGGGTC
AAGGA (CDR-H3), 
GTCTATTATTGTGCTCGCVGTTMTVGTTMTVGTTMTVGTTMTVGTGSTWTKGACTACTGGG
GTCAAGGA (CDR-H3), 
GTCTATTATTGTGCTCGCTMTVGTTMTVGTTMTVGTTMTVGTTMTGSTWTKGACTACTGGG
GTCAAGGA (CDR-H3). In these sequences, the designed codons for variable sites are 
underlined (M = A or C; V = A, C, or G). Codons of the structural residues important for CDR 
chain conformation integrity, shown in italics, are randomized to encode the naturally abundant 
amino acid types (Y = C or T; N = A, T, C, or G; S = C or G; W = A or T; K = G or T), similar to 
that described by Fellouse et al.(87). These primers were phosphorylated individually using T4 
polynucleotide kinase (NEB) as described (42). In the optimized Kunkel mutagenesis, the 
reaction mixture contains 0.33 µg of each of the phosphorylated Kunkel primers for the light 
chain CDRs and CDR-H1 and CDR-H2, 0.11 µg of each of the six Kunkel primers for CDR-H3, 
20 µg of the ssDNA of the Fab stop template (pFyes1), 50 mM Tris-HCl (pH 7.5), and 10 mM 
MgCl2 in a total 250 µl volume. This mixture was incubated at 95 
oC for 2 min, 50 oC for 3 min 
and then room temperature for 5 min. After annealing, 1 µl of 100 mM ATP, 10 µl of 25 mM 
dNTPs, 15 µl 100 mM DTT, 2400 units of T4 DNA ligase, and 30 units of T7 DNA polymerase 
were added sequentially and the mixture was incubated at room temperature overnight. After 
the polymerization and ligation step, the reaction mixture were purified on a QIAquick column 
(Qiagen), eluted with 35 µl ultrapure H2O, electroporated into electrocompetent SS320 cells, 
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and co-transfected with M13KO7 helper phage to obtain the YSGR Min library according to the 
published procedure (98). 
3.4.5 Phage display selection for RNAs 
 
For selection, the 3' tagged RNAs were first incubated with 1.1 eq of 5'-biotinylated DNA 
oligonucleotide,  5'-ACCGGGGATCCTCTAGAGTC-3', in the presence of 10 mM Tris-HCl (pH 
7.5) and 200 mM NaCl at 90 oC for 1 min and room temperature for 10 min to form the annealed 
RNA target complex. In the first round, 0.5 nmol of the RNA target complex was immobilized on 
streptavidin-coated magnetic beads (Promega), blocked with biotin, and incubated with ~1012-13 
cfu (colony forming unit) of phage for 15 min in 1 ml Binding Buffer (PBS [8 mM Na2HPO4, 1.5 
mM KH2PO4, pH 7.2, 137 mM NaCl, 3 mM KCl], 0.05% Tween 20, 2.5 mM EDTA, 12.5 mM 
MgCl2; for glycine riboswitches, 1 mM glycine was added to Binding Buffer) supplemented with 
0.1 mg/ml BSA, 0.1 mg/ml streptavidin, and 1 unit/µl RNase inhibitor (Promega). The beads 
were then separated from the solution on a magnet, washed twice with Binding Buffer, and 
directly used to transduce the XL1-blue cells to amplify the phage (74). In the subsequent 
rounds, purified phage were first incubated with streptavidin beads in Binding Buffer for 30 min 
to remove the bead binders and the supernatant was used in the subsequent selection on a 
KingFisher magnetic particle processor (Thermo Electron Corporation). Phage (~1010-11 cfu) 
were incubated for 15 min with 50 nM of the RNA target complex in 100 µl Binding Buffer, 
supplemented with 0.1 mg/ml BSA, 1 unit/µl RNase inhibitor, and 50 µg/ml E. coli tRNA mixture. 
Streptavidin magnetic beads were then added to the solution for 15 min to allow the capture of 
the RNA target complex together with the bound phage. The beads were then blocked with 50 
µM biotin, washed five times with Binding Buffer, and eluted in 50 µl elution buffer (PBS, 5% 
glycerol, 1 µg/ml biotinylated RNase A). The biotinylated RNase A was removed from the eluted 
phage by incubation with streptavidin beads. After each round of selection, recovered phage 
were amplified as described previously (74, 98).  
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3.4.6 Phage Enzyme-Linked Immunosorbent Assay (ELISA) for RNAs  
 
Phage ELISA for RNA-binding Fabs was adapted from the procedure described by 
Sidhu et al.(98). Forty-eight individual colonies were picked from a fresh LB/Amp plate (LB agar 
and 100 µg/ml ampicillin), inoculated in 400 µl of 2YT medium containing 100 µg/ml ampicillin 
and 1010 pfu/ml M13KO7 helper phage in a 96-well deep well plate, and grown at 37 oC 
overnight with shaking at 300 rpm. The deep well plate was then centrifuged for 15 min at 3500 
rpm to pellet the cells. The supernatant was diluted three fold to prepare a phage solution in 
Binding Buffer supplemented with 0.5% (w/v) BSA, 100 µg/ml sheared salmon sperm DNA, 0.67 
mg/ml heparin, and 1 mM vanadyl ribonucleoside complexes. A 96-well Maxisorp plate was 
coated with 100 µl of 2 µg/ml neutravidin in 100 mM sodium bicarbonate coating buffer (pH 9.6) 
overnight at 4 oC. The coating solution was removed and the Maxisorp plate was blocked for 1 h 
with 200 µl/well of 1% (w/v) BSA in PBS. After the blocking solution was removed, the Maxisorp 
plate was washed with PBS with 0.05% (v/v) Tween 20, then incubated with 100 µl/well 25 nM 
RNA target complex in Binding Buffer for 30 min at room temperature. For each well containing 
RNA target complex, a control well was prepared by incubation in Binding Buffer. The Maxisorp 
plate was then washed with Binding Buffer and incubated with 100 µl/well phage solution at 
room temperature for 30 min. After washing with Binding Buffer, the Maxisorp plate was 
incubated with 100 µl/well anti-M13/HRP conjugate (diluted 5000x in Binding Buffer 
supplemented with 0.5% (w/v) BSA and 1 mM vanadyl ribonucleoside complexes) at room 
temperature for 30 min. After another washing step with Binding Buffer, the Maxisorp plate was 
incubated with 100 µl/well Ultra TMB-ELISA Substrates (Pierce) for 5-10 min, quenched with 
100 µl/well 1 M phosphoric acid, and read spectrophotometrically at 450 nm in a microplate 
reader.  
3.4.7 Fab expression and purification 
 
A starter culture was inoculated with Fab plasmid containing E. coli 34B8 strain cells and 
was grown at 30 oC and 300 rpm overnight in 25 ml 2YT with 100 µg/ml ampicillin. 5ml of the 
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overnight starter culture was used to subculture 500 ml CRAP media (27 mM (NH4)2SO4, 2.4 
mM sodium citrate-2H2O, 14 mM KCl, 5.4 g/liter yeast extract,  5.4  g/liter  HyCase  SF  Casein,  
0.11  M  MOPS–NaOH buffer [pH 7.3], 0.55% [w/v] glucose and 7 mM MgSO4) supplemented 
with 100 μg/ml of ampicillin and grown at 30 oC and 300 rpm for 24 h. Cells were spun down at 
6000~8000 rpm for 10 min at 4 oC and the pellets were frozen at -20 oC overnight. 
The frozen cell pellets were thawed and lysed with lysozyme (0.3 mg/ml) and Dnase I 
(2.5mg/30ml) in 30 ml lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl, 0.5 mM PMSF) with 
vigorous stirring for 1 h at room temperature. Cell debris was centrifuged down and the 
supernatant was loaded onto a protein A column. The column was washed with 50 column 
volumes (CV) of 10 mM Tris pH 7.5, 500 mM NaCl and eluted with 0.1 M citric acid, pH 3. The 
eluate was collected in 3 ml fractions in tubes prefilled with 1.5 ml 1 M Tris pH 8.0 mixed 
immediately after elution to neutralize the solution. The eluate was then analyzed on a 10% 
SDS-PAGE gel, and the fractions of interest were pooled together.  
The pooled fractions were buffer exchanged into Low Salt NaOAc Buffer (10 mM 
NaOAc, pH 5.0, 50 mM NaCl) and loaded on a High S resin column packed in house. The 
column was washed and eluted with Low Salt NaOAc Buffer, and salt concentration was 
increased stepwise (from 50 mM to 500 mM NaCl). The eluate was analyzed on a 10% SDS-
PAGE gel and the fractions of interest were pooled together. The pooled Fab solution was 
buffer exchanged into Fab Storage Buffer (10 mM Tris pH 7.5, 50 mM NaCl), aliquoted and 
stored at -20 oC. 
3.4.8 Native Electrophoretic Mobility Shift Assay (EMSA) and Polyacrylamide 
Coelectrophoresis (PACE) 
 
 Native gel electrophoresis and polyacrylamide coelectrophoresis were carried out using 
a procedure adapted from that described previously (51). 20 pmol of RNA in 6.5 µl of 10 mM 
Tris-HCl (pH 7.5) was incubated at 95 oC for 2 min and room temperature for 2 min before the 
addition of 0.1 µmol MgCl2 and 1.5 µmol NaCl (for glycine riboswitches, 0.1 µmol glycine was 
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also added at this stage). After further incubation for 20 min, 10 µg heparin and 20 pmol of 
corresponding Fab was added to prepare a 10 µl mixture, which was incubated at room 
temperature for an additional 30 min. After homogenizing with 2 µl of native loading dye (50% 
glycerol, 0.1% xylene cyanol), the mixture was resolved via a 6% native PAGE in TB buffer 
containing 10 mM MgCl2 (for glycine riboswitches, PACE solution also contains 5 mM glycine). 
Electrophoresis was carried out with TB buffer containing 10 mM MgCl2 at room temperature for 
1 h under approximately 12.5 V per cm of gel height. 
3.4.9 Filter binding assay 
 
The binding constants of Fab with C209 P4-P6 and other RNAs were determined by 
filter binding assay. A constant concentration (~0.3 nM) of the 5'-32P-labeled RNA was 
incubated at 50 oC for 10 min in PEM buffer (PBS, 0.1 mM EDTA, 10 mM MgCl2; for glycine 
riboswitches, 10 mM glycine was added to the PEM buffer) and cooled to room temperature for 
10 min. The RNA was incubated for 30 min with Fabs ranging from 4 to 2000 nM in 40 µl PEM 
buffer supplemented with 1 mg/ml heparin. A BA85 nitrocellulose (S&S) and Hybond N+ filter 
(Amersham Pharmacia) were placed in the Dot-Blot apparatus (Bio-Rad) and the wells were 
pre-equilibrated with 100 µl PEM buffer. The Fab-RNA mixture was applied to the Dot-Blot 
apparatus and rinsed with 100 µl PEM buffer five wells at a time. Both filters were air dried and 
exposed to PhosphorImager screens, and the amount of RNA bound to each of the filters was 
quantified using ImageQuant (Molecular Dynamics). Binding constants were calculated by fitting 
the data to the following equation: fraction bound = M  [Fab]n/( n
dK  + [Fab]
n), where Kd is the 
binding constant; M is the maximum fraction of RNA bound at the highest Fab concentration; 
and n is the Hill coefficient. 
3.4.10 Competitive filter binding assay 
 
To determine the FSI value of each Fab, a filter binding assay was first carried out to 
determine the binding affinity (Kd) of the Fab binding to its cognate RNA. In the competitive filter 
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binding assay, a constant concentration (~0.3 nM) of the 5'-32P-labeled cognate RNA was 
incubated at 50 oC for 10 min in PEM buffer (PBS, 0.1 mM EDTA, 10 mM MgCl2; for glycine 
riboswitches, 10 mM glycine was added to the PEM buffer) and cooled to room temperature for 
10 min. The RNA was incubated for 30 min with its selected Fab at a concentration equal to 2Kd 
in 40 µl PEM buffer. In seven other reactions, the mixture was incubated with 2Kd concentration 
of one of the seven non-radiolabeled non-cognate RNAs from the following list: P4-P6, FNI-II, 
VCI-II, ExD1, AMTHF, DASAH, tRNA, CBATHF. A BA85 nitrocellulose (S&S) and Hybond N+ 
filter (Amersham Pharmacia) were placed in the Dot-Blot apparatus (Bio-Rad) and the wells 
were pre-equilibrated with 100 µl PEM buffer. The Fab-RNA mixture was applied to the Dot-Blot 
apparatus and rinsed with 100 µl PEM buffer five wells at a time. Both filters were air dried and 
exposed to PhosphorImager screens, and the amount of RNA bound to each of the filters was 
quantified using ImageQuant (Molecular Dynamics). The percent binding of the reaction without 
non-cognate RNA competitor was used as the reference point. The percent binding values 
obtained with seven non-cognate RNA competitors were then averaged, divided by the 
reference point, and averaged over two independent experiments to give FSI value for a given 
Fab RNA target pair, where 0 is completely nonspecific and 1 is completely specific. 
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CHAPTER 4 TOWARDS A HIGH RESOLUTION CRYSTAL STRUCTURE OF THE 
GLYCINE RIBOSWITCH 
4.1 Introduction 
 
Our understanding of RNA’s role in life processes has expanded greatly since the initial 
discovery of structured cleaving ribozymes over three decades ago. Besides canonical coding 
mRNA, non-coding RNAs exist with many manifestations mediating genetic expression and 
regulation such as histone modification, DNA methylation, metabolite sensing, post 
transcriptional gene silencing, intron splicing, trans RNA processing, and ribozymes involved in 
rolling circle replication (47, 107, 108). Non-coding RNAs have also been implicated in disease 
processes such as cancer, autism, obesity, Alzheimer’s, and atherosclerosis (109-119).  
RNA often assumes complex tertiary structures to execute its functions by interacting 
with proteins, other RNA, DNA, or small molecules; tRNA is a prime example of an RNA that 
does not encode information but rather folds into a complex tertiary structure to execute its 
function. Therefore, determining high resolution RNA structures will blaze the trail towards 
further understanding RNA mediated genetic regulation and potential diagnostic and clinical 
applications. For example, such structures allow understanding of RNA catalysis, methods of 
specific and high affinity metabolite binding, and interaction with other molecules in life 
processes, i.e. translation assemblies. Far more protein structures, however, have been 
determined than RNA; of the 81,103 x-ray diffraction structures currently in the PDB, less than 
2.5% contain RNA. This reflects the inherent difficulty of RNA crystallography and current lack 
of a systematic method to accomplish RNA crystallization.  
Crystal packing of RNA is difficult because of the large amount of anionic surface area; 
the repetitive anionic phosphate backbone can create imperfectly replicable packing, slipping 
slightly out of register. RNA’s limited chemical diversity relative to proteins (4 bases with 
relatively similar structure vs. 20 amino acids with a larger variety of structures, more potential 
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for interactions) is also seen as an impediment to packing (77, 120). Both chemicals and 
RNases degrade RNA, making the precursor crystal solution more heterogeneous, impeding 
high order ergo quality crystal formation. RNA structure is also more flexible than a protein of 
similar mass, perhaps again due to anionic repulsion, which also is counterproductive to a 
regular crystalline lattice. In addition to crystal formation difficulties, phasing is also problematic. 
Unlike selenomethionine mutant facilitated phasing in protein crystallography(120), RNA 
crystallography often relies on the large atoms from heavy metal ‘soak and pray’ methods to 
obtain phase information by methods such as MAD/SAD (multi-/single wavelength anomalous 
dispersion).  Other options for phasing include large bromine in the form of brominated/iodated 
uridine in sequences (34)  and a three base pair heavy metal binding motif engineered to 
facilitate heavy metal ion binding (121). Obtaining crystals can be challenging enough, but these 
phasing approaches often require making multiple batches of crystals to obtain complete 
diffraction data/phase information which is another issue if the crystals are not isomorphic/metal 
inclusion is sporadic. 
Fab chaperone assisted RNA crystallography (CARC) is an RNA crystallization method 
which uses Fab (antigen binding antibody fragments) as chaperones. Fab CARC provides 
surface protein chemical diversity for crystal contact formation and decreases surface anionic 
content to promote packing while also addressing phasing issues, as its presence will provide a 
large structure for molecular replacement phasing. A library of Fabs fused to a phage coat 
protein is used in phage display selection against RNA to isolate Fabs binding to a particular 
RNA target, an in vitro technique required since an RNA antigen cannot be injected into a host 
for hybridoma development of antibodies due to degradation. Fab CARC successfully 
crystallized Tetrahymena Group I intron P4-P6 domain (PBD: 2R8S)(74) and Class I Ligase 
(3IVK)(75) structures. Fab mediated crystal contacts provided 61% and 59% of the total solvent 
accessible surface area buried in crystal contacts for P4-P6 and the Ligase, respectively. 
Moreover, crystal structures of the Class I Ligase chaperoned with Fab protein proved much 
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less arduous to phase than the U1A version (75). Fabs are also beneficial as they can be 
selected against an unengineered structure using the phage display technique, requiring little 
previous knowledge of its functional residues; such knowledge is required if mutational 
approaches to crystallization/phasing are employed. Raising Fab against novel RNA in cells 
could allow specific RNA immunostaining and identification of disease markers, to name a few 
other possibilities. 
Well structured RNAs for which crystal structures can be obtained (as opposed to 
unstructured RNAs which may still have a biological function) are comprised of more than just 
the previously mentioned tRNA and Group I/Group II introns; another class of structured RNA is 
the riboswitch. Riboswitches are structured motifs usually upstream of start codons that bind a 
small molecule (often metabolite) and undergo a conformational change which, most frequently, 
inhibits or activates translation or transcription, occasionally with protein assistance (47). In 
addition to the basic research goal of elucidating the exact atomic mechanism of gene 
regulation, a riboswitch structure is useful for applied research, allowing structure based design 
of new antibiotics. The basis for functioning of the antimicrobial compound pyrithiamine has 
been shown to be the TPP riboswitch, lysine analogues target the lysine riboswitch, and 
roseoflavin targets riboflavin riboswitches; riboswitch mutants that no longer effectively regulate 
translation show resistance (122). Since initial realizations of the mechanism of these previous 
antibiotics, analogues for c-di-GMP and guanine have been designed for their riboswitches 
(123-126). A trial testing Staphylococcus aureus bovine intramammary infection with the 
guanine analogue 2,5,6-triaminopyrimidine-4-one showed some positive results (127). The 
glycine riboswitch is an especially novel gene regulator with its dual aptamer configuration, the 
purpose of which is still uncertain (6, 51). It is upstream of the gcvT operon, involved in glycine 
cleavage; glycine is an important part of bacterial metabolism, making it a reasonable target for 
antibiotics. Accordingly, the last portion of this research attempts to crystallize the glycine 
riboswitch.  
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The crystal structure of the dual aptamer truncated FNI-II riboswitch (19) and of an 
individual aptamer from species Vibrio cholerae (VC) (18), were obtained by other laboratories. 
The FNI-II glycine riboswitch (truncated glycine riboswitches) behaves much differently than the 
FNLD (contains leader sequence, full length riboswitches) riboswitch, however. Studied more in 
depth in the VC version of the truncated riboswitch (VCI-II) (51), a mutation in one aptamer that 
prevented it from binding glycine also weakened the other aptamer’s ability to bind glycine, 
leading to the idea of glycine binding cooperativity. However, such is not the case with VCLD; 
even with one aptamer’s mutation-induced lack of glycine binding, the other was still able to 
bind glycine. Furthermore, the full length glycine riboswitches (VC, FN, and Bacillus subtilis) 
bind glycine with a lower Kd of about 5 µM (now similar for these species, which was not the 
case for truncated versions); the kink-turn may further preorganize the glycine binding sites. 
Because of this new data, a new structure of the glycine riboswitch is obviously needed. FNLD 
is chosen due to smaller size since smaller targets crystallize more readily.  
The approach that yielded the FNI-II structure involved mutating the P2 loop of aptamer 
I, which influenced the following work. The Class I Ligase structure’s Fab BL3-6 bound to a 
portable RNA loop which was mutated into the same location in FNLD as was done for FNI-II. 
Several Fab and RNA combinations based on this, along with hundreds of crystallization 
conditions, have been attempted. Preliminary crystals have been diffracted but to insufficient 
resolution. Several further approaches are also posited to attempt to achieve a sufficiently high 
enough resolution crystal. 
4.2 Results 
 
The FNI-II structure was obtained using a smaller chaperone protein, the U1A protein. It 
should be noted that it is only about 11 kiloDaltons (kD), while a Fab is 48 kD, much larger, 
therefore facilitating phasing by molecular replacement of its large known structure. The U1A 
protein has a small sequence of RNA that is its cognate ligand. In the FNI-II structure (19), 
aptamer I’s P2 loop was replaced with this based upon previous information that mutating this 
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location should be innocuous, and this construct is what allowed FNI-II cocrystallization with 
U1A. Based upon the success of this approach, a similar approach was taken in the hopes of 
expediting crystallization. The aforementioned Class I Ligase crystal’s cognate Fab BL3-6 
actually bound to a loop of the ligase as well, creating a portable Fab/ligand nucleotide 
sequence pair. This GAAACAC loop sequence was mutated into the same location in aptamer I 
P2, and the RNA construct FNLDP2 was made in crystallization quantity, followed by large 
scale expression of BL3-6. After expression, BL3-6 was purified through protein A affinity, High 
S cation exchange gravity flow column chromatography, and finally, Superdex 200 gel filtration 
with an AKTAprime Plus. All of these steps purify the Fab, as having a pure sample is very 
important for packing into a regular crystalline lattice. This purification is also important to 
remove RNases that are present from the E. coli 34B8 expression system from which Fab is 
obtained by cell lysis. Fab is tested for nuclease activity by incubation with non cognate 32P 
radiolabeled RNA, fragments of which are then separated by denaturing polyacrylamide gel 
electrophoresis (dPAGE). This is visualized by autoradiography and subsequently quantified. 
Once Fab and RNA were purified, the pair was checked for complexation with a 
polyacrylamide native gel and the 176 nM Kd was determined by filter binding (dot blot) assay.  
The native complexation gel was done with stoichiometric excesses of Fab (1, 1.1, 1.2, 1.3, 1.4 
equivalents; concentrations of Fab and RNA are determined with computational constants and 
may be slightly incorrect) from which the lowest amount that gave as complete a shift as a 
possible was chosen as the crystallization stoichiometry (Fig 4.1). With this stoichiometry a 
Fab/RNA complex solution was formed, and screening trays were set up. Screening comprised 
of 96 well sitting drop plates of Natrix 1&2, Crystal Screen 1&2, and Index 1&2 crystal solution 
kits from Hampton Research; duplicates were made for 15 and 4 °C for a total of nearly 600 
conditions.  
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Figure 4.1 Native complexation gel of FNLDP2 and BL3-6.  
 
The first lane is folded RNA, followed by 1, 1.1, 1.2, 1.3, and 1.4 equivalents of BL3-6. The 
lanes containing Fab show a higher band, the Fab RNA complex.  
 
From these, two initial conditions were obtained, one at each temperature. After about 
one month, Index condition D3 at 4 °C contained a crystal shower, resembling rectangles (Fig. 
4.2 left). At 15°C, Index F9 showed needle clusters after about two and a half weeks (Fig. 4.2 
right). These two conditions were used as a starting point for variations in the percent of their 
respective precipitants as well as variations upon their pHs in 24 well hanging drop optimization 
trays. Once a course optimization was done (ex. pH increments of 0.5 and ± several percent 
precipitant on either side of the initial condition) and a condition was chosen from this, a fine 
optimization with smaller increments was done to further refine conditions. During the course of 
optimizations, a new batch of BL3-6 needed to be made, which resulted in some repetition of 
effort. Crystal reproducibility was sporadic, however (perhaps in part due to the new batch of 
Fab), with different formations of needle clusters for F9 or a much longer incubation time 
needed for the D3 condition. Consternatingly, also the F9 needles often had loosely aggregated 
quasi-crystal ‘blobs’/spherulites in addition to or in place of the needles clusters themselves, a 
situation which is not noted as helpful for crystallization by crystallographers. Some optimization 
trays were done altering the ratio of well solution to complex solution; typically, they are 1:1, but 
2 µl complex:1 µl well solution and 0.5 µl complex:1 µl well solution were also used. Half of an 
optimization tray was made for the D3 condition to contain complex with 10mg/ml, slightly lower 
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than the usual 12mg/ml, and the other half had a slightly stoichiometrically altered ratio of Fab to 
RNA in the complex solution. A few conditions related to F9 showed similar crystal formation at 
a later date, and an optimization tray was made exploring this. Unfortunately, none of these and 
other variations attempted lead to any definite improvement in reproducibility or morphology 
(single crystals are usually best for diffraction, but the needle clusters are far from this ideal). 
 
Figure 4.2 Initial crystal hits. 
 
Left, initial rectangular Index D3 crystals surrounded by precipitate. Right, initial Index F9 needle 
crystals with phase separation. This picture does not show many quasi-crystal ‘blobs’ or 
spherulites also present in the F9 condition, though one is obvious in the lower right corner. 
 
From these roughly two dozen optimization trays along the ideas listed above, there was 
a D3 tray from which large rectangular crystals were harvested and sent for initial diffraction 
testing to Brookhaven National Laboratory courtesy of Annie Heroux. They contained a large 
quantity of water (~70%) and diffracted only weakly, roughly an 8 Å resolution (about 4-5 Å too 
high for current standards). Another tray was set up with similar conditions after this result, and 
the relative dimensions of the rectangular crystals which grew were altered. These were 
harvested under two conditions, one with normal cryoprotectant solution, the second under 
conditions that attempted to dehydrate the crystals to remove excess water and improve 
diffraction. Post crystallization dehydration treatment has been noted to improve the diffraction 
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of some crystals (128, 129). Showing how difficult it is to judge a crystal by its appearance, 
despite the different relative dimensions, this second batch of crystals diffracted equal to or just 
slightly better than (6-7Å) the previously diffracted batch, including the dehydrated crystals, for 
which no observable change was noted during dehydration (i.e. cracking) as has been for some 
crystals that underwent successful, resolution improving dehydration. 
The addition of additives is known to assist crystal formation. As such, additive screens 
for both of these conditions were performed using Hampton Research’s additive screen kit. For 
the F9 condition, the additive screen did indeed result in more frequent crystal formation. 
Unfortunately, however, most conditions still contained quasi crystals, and the overall 
morphology was similar to that seen previously, various types of needle clusters ill suited for 
diffraction. The additive screen for the D3 condition showed better results. Many different wells 
contained crystals, from rectangular showers of a multitude of smaller crystals, wells with a far 
smaller number but larger size of crystals, intermediates to these, and even some wells where 
the morphology changed to rod clusters. This additive screen was also encouraging since the 
time for initial D3 crystal formation was on the order of weeks instead of months. These 
underwent diffraction testing, at best resulting in ~5.3 Å, and some of them are pictured in Fig. 
4.3. As was the case previously, here none of the dehydration conditions (one with EtOH, the 
other with increased precipitant) produced any discernible resolution improvement relative to 
those simply harvested in cryoprotectant. 
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Figure 4.3 Several different D3 additive crystal drops.  
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Concurrently with the additive tray approach, four mutants of the P2 base paired stem 
below the loop in the FNLD RNA were made, adding or removing one or two base pairs to 
create FNLDP2b, FNLDP2c, FNLDP2d, and FNLDP2e RNAs. Altering stem length changes the 
orientation of Fab relative to the RNA target due to helical rotation, altering three dimensional 
structures, and has proven helpful in crystallization (130) (also suggested by Barbara Golden in 
personal communication). Though the lengthened mutants did not prove very fruitful, the 
shortened ones did show formation of a handful of crystals, mostly from FNLDP2d, though one 
interesting morphology was obtained through FNLDP2e. In addition, based upon work by others 
in the laboratory, a Fab mutant was made called BL3-6 BS1 for use in crystallization. BS1 
stands for beta sheet 1 mutant, mutations created to strengthen a beta sheet contact present in 
the P4-P6 Fab 2 crystal structure. BL3-6 BS1 combined with FNLDP2 created many small 
showers; these have yet to be explored extensively in additional trays. 
4.3 Discussion and Future Directions 
 
Though currently no useful diffraction data has been obtained, especially given the 
increase in crystal formation due to the additive screen, there are still many efforts that can be 
attempted, some of which have been mentioned in context in the previous section. One 
approach would be to slightly elevate the temperatures of the additive screen tray conditions 
which showed showers of a multitude of crystals, as increasing the temperature may slow the 
crystal formation to allow a smaller number but larger size of crystal to be formed, though the 
more common remedy to this is seeding, mentioned below. 
The F9 condition with additive screen well F10 seemed to reduce needle clusters to 
individual needles, possibly useful for seeding. Seeding is the process of inserting a small 
crystal (mactroseeding) or small crystal pieces (microseeding, streak seeding) into a crystal 
drop in an effort to grow one or a few large crystals for diffraction, as crystals need to be large 
enough (perhaps about 100 microns) to allow collection of enough data. This approach might 
also be taken for the D3 wells as well, especially with some of the new rod clusters, a different 
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morphology which grew somewhat smaller crystals in a shower. This approach may further be 
advisable due to the large D3 unit cell (~120x120x915), as one potential remedy to a larger unit 
cell crystal with weak diffraction is to make a larger crystal containing more unit cells in hopes of 
increasing diffraction (increasingly larger crystals could be seeded to further increase their size). 
Lastly, there were multiple small showers for especially the FNLDP2d stem mutants, which may 
be useful in crystal seeding. 
As previously mentioned, dehydration or other post crystallization treatments may also 
allow a crystal that does not quite diffract to high enough resolution to increase a few Angstroms 
to sufficient resolution. Mutations have been done to the Group I intron to improve its 
crystallizability as well(128, 130-132); a similar approach might be taken with this riboswitch. 
Several different Fabs were also raised against FNI-II. The YSGR Minimal library 
produced FNI-II Fab 16, and FNI-II Fabs 4, 8, and 9 were selected from the YSGRX library. 
These could all be checked for complexation with FNLD constructs (16 and 4 are first choice 
due to lower Kd values), then used in crystal trays if the Fabs bind. Another Fab approach is 
surface entropy reduction (SER) of Fabs, or mutating flexible, protruding surface residues into 
smaller, less obtruding residues. This approach was done for the Fab 2 P4-P6 crystal by 
another individual in this laboratory, showing encouraging results in formation of crystals in 
additional conditions (additional ‘hits’) (42). SER super mutant alanine or serine (SMA/SMS) 
versions of any of the above five Fabs (4, 16, 8, 9, and BL3-6) may prove helpful in 
crystallization. SMA/SMS Fab expression plasmids of BL3-6, Fab 4, and Fab 16 have already 
been created. Along similar lines, the previously mentioned beta sheet 1 (BS1) mutation 
designed to improve the P4-P6/Fab 2 crystal’s beta sheet interaction has already shown some 
promise in screening trays on the Fab BL3-6 (namely, BL3-6 BS1/FNLDP2). The Fab 2 BS1/P4-
P6 complex actually produced solvable diffraction data which is why the BS1 mutations were 
chosen over BS2, though a BL3-6 BS2 Fab expression plasmid has also already been created. 
If additional optimization, additive, and seeding approaches do not provide well resolved 
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diffracting crystals with any of the five RNA stem construct variations in combination with Fab 
BL3-6 BS1 (or any of its other mutants), BS1 and BS2 mutations could also be done to any of 
the other Fabs (4,8,9,16). 
4.4 Materials and Methods 
 
4.4.1 RNA Preparation 
 
The previously constructed glycine riboswitch FNI-II was generated by annealing DNA 
oligonucleotides (Integrated DNA Technologies) and amplified by recursive PCR (55) with an 
EcoRI restriction site and T7 promoter sequence engineered at the 5’ terminus, and EarI and 
HindIII sites engineered at the 3’ terminus. Double digested (EcoRI/HindIII, New England 
Biolabs protocol, 37°C for 1 hour, NEB buffer 2) riboswitch DNA inserts and pUC19 vector were 
ligated together (T4 DNA ligase, New England Biolabs protocol, 16°C overnight) to generate the 
plasmid. FNLD was previously constructed from FNI-II (51) by Quikchange and used as a 
template for FNLDP2, FNLDP2b, FNLDP2c, FNLDP2d, FNLDP2e which were constructed by 
QuikChange site-directed mutagenesis (Stratagene) from the FNLD plasmid and proper DNA 
oligonucleotide primers (see primer table below). The plasmids were transformed into JM109 
cells, amplified and purified with Qiagen’s miniprep plasmid preparation kit, and their sequences 
were confirmed by sequencing (Eton BioScience Inc.). More of the correct resulting plasmids 
were produced with Qiagen’s maxiprep kit and were then linearized with EarI (New England 
Biolabs, 0.2 unit per µg of plasmid, NEB buffer 4, 37°C overnight) for transcription by T7 RNA 
polymerase.  
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Construct Primer Sequence (added Fab binding loop in bold, inserted base 
pairs red)     
FNLDP2 FNLDP2Fwd CGGATGAAGATATGAGGAGAGATTTCATGAAACACATGAA
ACACCGAAGAAGTAAATC 
  FNLDP2Rvs GATTTACTTCTTCGGTGTTTCATGTGTTTCATGAAATCTCTC
CTCATATCTTCATCCG 
FNLDP2b FNLDP2bFwd CGGATGAAGATATGAGGAGAGATTTCATCGAAACACGATG
AAACACCGAAGAAGTAAATC 
  FNLDP2bRvs GATTTACTTCTTCGGTGTTTCATCGTGTTTCGATGAAATCTC
TCCTCATATCTTCATCCG 
FNLDP2c FNLDP2cFwd GATGAAGATATGAGGAGAGATTTCATACGAAACACGTATG
AAACACCGAAGAAGTAAATC 
  FNLDP2cRvs GATTTACTTCTTCGGTGTTTCATACGTGTTTCGTATGAAATC
TCTCCTCATATCTTCATC 
FNLDP2d FNLDP2dFwd CGGATGAAGATATGAGGAGAGATTTCAGAAACACTGAAAC
ACCGAAGAAGTAAATC 
  FNLDP2dRvs GATTTACTTCTTCGGTGTTTCAGTGTTTCTGAAATCTCTCCT
CATATCTTCATCCG 
FNLDP2e FNLDP2eFwd CGGATGAAGATATGAGGAGAGATTTCGAAACACGAAAC
ACCGAAGAAGTAAATC   
  FNLDP2eRvs GATTTACTTCTTCGGTGTTTCGTGTTTCGAAATCTCTCCTCA
TATCTTCATCCG 
 
RNAs were transcribed in 1 ml reaction mixture containing 40 mM Tris-HCl (pH 7.9), 2 
mM spermidine-3HCl, 10 mM DTT, 25 mM MgCl2, 5 mM each of the nucleotide triphosphates, 
50 µg/ml  linearized plasmid, 0.01 unit/µl 5 PRIMETM stop RNase inhibitor RX (5 PRIME life 
science), 8 mili unit/µl thermostable inorganic pyrophosphatase (New England Biolabs), and 45 
µg/ml T7 RNA polymerase (expressed and purified in-house) for 4 h to overnight at 37°C. The 
transcription mixture was incubated with 1 mM CaCl2 and RNase-free DNase I (Promega) at a 
concentration of 0.5 unit per µg of DNA plasmid at 37°C for 30 minutes. The RNA transcripts 
were purified by 6% to 8% denaturing PAGE, excised under UV TLC plate shadowing, 
electroeluted into ~15 ml TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA) in dialysis tubing, 
Amicon concentrated, PCA then CA extracted, ethanol precipitated, and redissolved in 1M pH 
6.5 Na cacodylate buffer to ~14-24mg/ml concentration (needed for later dilution in 
crystallization). RNA concentrations were determined by UV absorbance at 260 nm wavelength 
with extinction coefficients calculated by OligoCalc (57). After solvation, crystallization RNAs 
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were benchtop centrifuged and filtered through a Millipore 0.22 µm Ultrafree microcentrifuge 
tube device to remove any precipitate/particulate and flash frozen with liquid nitrogen for storage 
at -80 °C in small aliquots.  
4.4.2 Fab Expression and Purification 
 
Fab BL3-6 plasmid was provided by Dr. Piccirilli, University of Chicago, and 
electroporated into 34B8 cells. A starter culture was inoculated and grown at 30 oC and 300 rpm 
overnight in 25 ml 2YT with 100 µg/ml ampicillin. 5ml of the overnight starter culture was used 
per 500 ml subculture of CRAP media (27 mM (NH4)2SO4 , 2.4 mM sodium  citrate-2H2O,  14  
mM  KCl,  5.4  g/liter  yeast extract,  5.4  g/liter  HyCase  SF  Casein,  0.11  M  Mops– NaOH 
buffer [pH 7.3], 0.55% [w/v] glucose and 7 mM MgSO4) supplemented with 100 μg/ml of 
ampicillin and grown at 30 oC and 300 rpm for 24 h. Cells were spun down at 6000~8000 rpm 
for 10 min at 4 oC and the pellets were frozen at -20 oC overnight. Over the course of all of the 
crystal trays, several dozen liters were grown in a total of three batches.  
The frozen cell pellets were thawed and lysed with lysozyme (9mg/30ml), Dnase I 
(2.5mg/30ml) in 30 ml lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl, 0.5 mM PMSF) per 500ml 
pellet which was completely resuspended before vigorous stirring for 1 h at room temperature. 
Cell debris was centrifuged down and the supernatant was loaded onto a protein A column at 4 
oC which was previously equilibrated with 20CV of TBS (10 mM Tris pH 7.5, 150 mM NaCl). The 
column was washed with 50 column volumes (CV) of 10 mM Tris pH 7.5, 500 mM NaCl and 
eluted with 0.1 M citric acid, pH 3. The eluate was collected in 3 ml fractions in tubes prefilled 
with 1.5 ml 1 M Tris pH 8.0, mixed immediately after elution to neutralize the solution, and 
analyzed on a 10% SDS-PAGE gel. The fractions of interest were pooled together. 
The pooled fractions were dialyzed into Low Salt NaOAc Buffer (10 mM NaOAc, pH 5.0, 
50 mM NaCl, 4L per eluate from two 5mL protein A columns divided into three aliquots) and 
loaded at 4 oC on a High S resin gravity flow econo column packed in house previously washed 
with 20CV of Low Salt NaOAc Buffer. The column was washed and eluted with Low Salt NaOAc 
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Buffer and stepwisely increased salt concentration (90% low salt, 10% high salt 500mM NaCl 
buffer, 80/20, etc., from 50 mM to 500 mM NaCl). Fractions were checked for protein at 280nm, 
(extinction coefficients obtained from the expasy.org ProtParam tool) the eluate was analyzed 
on a 10% SDS-PAGE gel, and the fractions of interest were pooled together in an Amicon so 
that no more than 5mg was in 250µl for quantitative recovery from a gel filtration column.  
Before loading on a gel filtration column, a portion of the Fab was diluted to about 
0.4mg/ml (approximate High S fraction concentration) in one tube and 6mg/ml (approximate 
crystallization drop concentration) in another tube (final incubated concentrations) in an assay 
with 0.5µl ~10kcpm radiolabeled (see procedure below) non cognate RNA (0.5 hours, 37 °C). 
Final volume of 9.5 µl is accomplished with Fab storage buffer (10 mM Tris pH 7.5, 50 mM 
NaCl).  TE buffer and Fab storage buffer with RNA only are each done in an additional tube for 
comparison, RNase contamination control. Fragments are electrophoretically size separated by 
8% polyacrylamide gel, the gel is dried, exposed to PhosphorImager cassettes overnight, and 
quantified with ImageQuant software (Molecular Dynamics). The rule of thumb is if the Fab 
sample has less than ~10% additional degradation relative to the lanes that contain buffer only, 
it is then purified by gel filtration. Otherwise, another round of High S is performed. 
Fab gel filtration is performed with a Superdex 200 10x300mm column connected to an 
AKTAprime plus at 4 oC for final polishing, removing proteases/RNases and increasing Fab 
homogeneity. Based upon manufacturer’s guidelines for maximum recovery, we load ~250 µl 
and ~5 mg into a 0.5 ml loop that has been first benchtop centrifuged and transferred into a new 
microcentrifuge tube to remove precipitate. The sample is monitored at 254 nm. At a flow rate of 
0.4 ml/min., we collect ~0.5 ml fractions that begin to elute ~45 min. Useful fractions are 
concentrated and buffer exchanged into Fab storage buffer with an Amicon centrifugal 
concentrating device (~14-24 mg/ml), aliquoted in small fractions, and immediately frozen in N2(l) 
for storage at -80 oC. 
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4.4.3 5’ end 32P labeling of RNAs 
 
In a typical procedure, 40 pmol RNA transcript was dephosphorylated by incubation with 
1 unit of shrimp alkaline phosphatase (Fermentas Life Sciences) in the supplied phosphatase 
buffer in a total volume of 10 µl at 37 oC for 30 min. After incubation at 65 oC for 15 min to 
inactivate the phosphatase, 1 µl sterile H2O, 1.5 µl 10× T4 polynucleotide kinase buffer (New 
England Biolabs), 2 µl -32P ATP (Perkin Elmer), and 0.5 µl 10 unit/µl T4 polynucleotide kinase 
(New England Biolabs) were added and the reaction mixture was incubated at 37 oC for 30 min 
for RNA phosphorylation. For RNA transcripts with the 5’ end buried by or too close to a duplex 
region, to improve the labeling yield, the transcripts were first annealed to a DNA 
oligonucleotide to free the 5’ end before dephosphorylation and phosphorylation reactions. After 
phosphorylation, 32P-labeled RNAs were purified by 6-8% denaturing polyacrylamide gel 
electrophoresis, visualized on an x-ray film, excised, and passively eluted in 300 µl TE buffer on 
a rotator at 4 oC overnight. After centrifugation, the radiolabeled RNAs were PCA extracted 
twice, EtOH precipitated, and redissolved in TE buffer. 
4.4.4 Native Electrophoretic Mobility Shift Assay (EMSA) and Polyacrylamide 
Coelectrophoresis (PACE) 
 
Before setting up each new crystal tray with a new Fab/RNA pair, a native gel was done 
to confirm their complexation and determine complex (Fab:RNA) stoichiometry. Native gel 
electrophoresis/polyacrylamide coelectrophoresis was carried out using a procedure adapted 
from that described previously.(51) 20 pmol of RNA in 6.5 µl of 10 mM Tris-HCl (pH 7.5) was 
incubated at 95 oC for 2 min and room temperature for 2 min before the addition of 0.1 µmol 
MgCl2 and 1.5 µmol NaCl (for glycine riboswitches, 0.1 µmol glycine was also added at this 
stage). After further incubation for 20 min, 10 µg heparin and 20 pmol of corresponding Fab was 
added to prepare a 10 µl mixture, which was incubated at room temperature for an additional 30 
min. After homogenizing with 2 µl of native loading dye (50% glycerol, 0.1% xylene cyanol), the 
mixture was resolved via a 6% native PAGE in TB buffer containing 10 mM MgCl2 (for glycine 
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riboswitches, PACE solution also contains 5 mM glycine). Electrophoresis was carried out with 
TB buffer containing 10 mM MgCl2 at room temperature for 1 h under approximately 12.5 V per 
cm of gel height.  
4.4.5 Filter binding/dot blot assay 
 
The binding constant of Fab BL3-6 with FNLDP2 was determined by filter binding assay. 
A constant concentration (~0.3 nM) of the 5'-32P-labeled RNA was incubated at 50 oC for 10 min 
in PEM buffer (PBS, 0.1 mM EDTA, 10 mM MgCl2; for glycine riboswitches, 10 mM glycine was 
added to the PEM buffer) and cooled to room temperature for 10 min. The RNA was incubated 
for 30 min with Fabs ranging from 4 to 2000 nM in 40 µl PEM buffer supplemented with 1 mg/ml 
heparin. A BA85 nitrocellulose (S&S) and Hybond N+ filter (Amersham Pharmacia) were placed 
in the Dot-Blot apparatus (Bio-Rad) and the wells were pre-equilibrated with 100 µl PEM buffer. 
The Fab-RNA mixture was applied to the Dot-Blot apparatus and rinsed with 100 µl PEM buffer 
five wells at a time. Both filters were air dried and exposed to PhosphorImager screens, and the 
amount of RNA bound to each of the filters was quantified by using ImageQuant (Molecular 
Dynamics). Binding constants were calculated by fitting the data to the following equation: 
fraction bound = M  [Fab]n/( n
dK  + [Fab]
n), where Kd is the binding constant; M is the maximum 
fraction of RNA bound at the highest Fab concentration; and n is the Hill coefficient. 
4.4.6 Fab surface protein residue mutations (BS1/BS2/SMA/SMS) 
 
The parent phagemid of BL3-6, designed to display bivalent, humanized Fab on the 
surface of M13 bacteriophage, has been described previously (42). Electroporation of this 
phagemid into CJ236 cells (uracil deglycosidase/dUPTase deficient) generated uracil-containing 
ssDNA by following the procedure as described (42). Various Kunkel primers were designed to 
insert the SMA/SMS/BS1/BS2 (see primer table below, LC light chain, HC heavy chain) 
mutations through Kunkel mutagenesis (97). After phosphorylation using T4 polynucleotide 
kinase, these primers were annealed with uracil-containing ssDNA of BL3-6 (or other parent 
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Fab on which these mutations were desired), extended with T7 DNA polymerase, ligated with 
T4 DNA ligase, cleaned with PCA extraction/EtOH precipitation, and transformed into XL1-blue 
cells (uracil glycosidase/dUTPase containing strain) to generate a phagemid following the 
procedure as described (42). Small scale DNA was purified using Qiagen’s miniprep kit and 
sent for sequence confirmation (Eton Bioscience Inc.).  
Fab Primer Sequence 
BL3-6 
BS1 
  
LCE123A CTTCATCTTCCCGCCATCTGATGCCCAGTTGAAATCT
GGAACTGC 
Bsheet1 
K214A, D216T, K217A, 
K218T, E220A, stop codon 
CACAAGCCCAGCAACACCGCCGTCACCGCCACCGTT
GCCCCCAAATCTTGTGACAAAACTCACACATAGGGC
CGGCCCTCTGGTTCC 
BL3-6 
BS2 
  
LCE123A CTTCATCTTCCCGCCATCTGATGCCCAGTTGAAATCT
GGAACTGC 
Bsheet2 
K214A, D216A, K217A, 
K218A, E220A, stop codon  
CACAAGCCCAGCAACACCGCCGTCGCCGCCGCCGT
TGCCCCCAAATCTTGTGACAAAACTCACACATAGGG
CCGGCCCTCTGGTTCC 
BL3-6 
SMA 
  
  
LCE123A CTTCATCTTCCCGCCATCTGATGCCCAGTTGAAATCT
GGAACTGC 
LCK190A AGCAGACTACGAGAAACACGCCGTCTACGCCTGCGA
AGTCA 
HCSM1stop  
K217A, K218A, E220A, 
stop codon 
AGCAACACCAAGGTCGACGCCGCCGTTGCCCCCAAA
TCTTGTGACAAAACTCACACATAGGGCCGGCCCTCT
GGTTCC 
BL3-6 
SMS 
  
  
LCE123S CTTCATCTTCCCGCCATCTGATAGCCAGTTGAAATCT
GGAACTGC 
LCK190S AGCAGACTACGAGAAACACAGCGTCTACGCCTGCGA
AGTCA 
HCSM2stop 
K217S, K218S, E220S, 
stop codon 
AGCAACACCAAGGTCGACAGCAGCGTTAGCCCCAAA
TCTTGTGACAAAACTCACACATAGGGCCGGCCCTCT
GGTTCC 
 
4.4.7 Crystallization complexation 
 
Before addition to crystal trays with crystallization solutions, Fab and RNA 
samples undergo a folding and complexation procedure. First, a 6-8% native 
polyacrylamide gel (EMSA described previously) is done with slightly differing RNA:Fab 
ratios (1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4) in individual lanes to determine the best 
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stoichiometry for each batch/new combination of Fab and RNA. Once this is 
determined, a large batch of complex with the empirically best ratio can be made for 
crystal trays. Buffers, microcentrifuge tubes, and pipette tips must be as RNase free as 
possible so that there is as little RNase present as possible in the drops during the 
potentially long incubation times. A 12mg/ml Fab/RNA complex is used (made in ~15% 
volume excess for pipette error), which is usually combined with one equivalent of well 
solution, though instances of 1:2 and 2:1 sample:well solution ratio have been 
attempted on occasion but did not produce useful crystals. This 12mg/ml complex is 
converted to moles for a 1:1 ratio, then whatever slight stoichiometric excess of Fab has 
been determined by native gel is added in addition to this value. MgCl2 has a final 
concentration in the complex solution of 20mM for RNA structure, 10mM pH 7.5 Tris 
HCl is used as a buffer and adjustable volume (as Fab and RNA concentrations vary 
from batch to batch), 50mM NaCl for Fab structure (Fab solvated in Fab storage buffer 
which contains 50mM NaCl already, so this must be subtracted from the final complex 
volume), 0.5U/µl final concentration of Superase RNase inhibitor (20U/µl tube, 
purchased through Invitrogen AM2696, made by Ambion). For the glycine riboswitch 
5mM glycine final concentration is also used. The final volume required depends upon 
the number of trays being set up; for example, for one 96 well sitting drop screening 
tray, 55.2 µl would be required (48 µl*1.15 excess pipette error volume), as 0.5 µl well 
solution is combined with 0.5 µl complex in each well. The complexing and folding 
procedure for a crystallization batch of RNA consists of adding calculated required 
volumes of RNA and Tris into a microcentrifuge tube; vortexing and centrifuging  down; 
heating to 95 °C for 2 min.; cooling at room temperature (RT) 2 min.; adding Mg, NaCl, 
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and glycine; vortexing and centrifuging down; RT 20 min.; adding Superase and Fab; 
vortexing and centrifuging down; 30 min. RT; centrifuge in a benchtop centrifuge for 5 
min. at max speed to pellet any particulates; and lastly, careful pipetting to remove 
complex to a new tube without disturbing any pellet, ready for addition to a tray. 
Hanging drop trays are usually 1 µl complex: 1 µl well solution on the cover slip, double 
volume from sitting drop. 
4.4.8 Crystal screening conditions 
 
Screening (FNLDP2, FNLDP2b, FNLDP2c, FNLDP2d, FNLDP2e, each with BL3-
6, and FNLDP2 with BL3-6 BS1) comprised of 96 well sitting drop plates of Natrix 1&2, 
Crystal Screen 1&2, and Index 1&2 crystal solution kits from Hampton Research; 
duplicates were made for 15 and 4 °C for a total of nearly 600 conditions. Initially 100 µl, 
then 80 µl well solution in later trays from a kit was placed in the main well, and up to 
the entire three sitting drops in one well were used, 0.5 µl complex solution combined 
with the same volume of well solution. Plates were sealed with Crystal Clear tape and 
left to incubate.  
From the BL3-6 trays, two initial conditions were obtained, one at each 
temperature. After about one month, Index condition D3 at 4 °C (0.1 M HEPES pH 7, 
30% v/v Jeffamine ED-2001 pH 7; no crystals at 15°) contained a crystal shower, 
resembling rectangles. At 15°C, Index F9 (0.2 M ammonium sulphate, 0.1 M Tris pH 
8.5, 25% w/v polyethylene glycol 3350; 4°, very small rosettes/spherulites) showed 
needle clusters after about two and a half weeks. These two conditions were used as a 
starting point for variations in the percent of their respective precipitants as well as 
variations upon their pHs in 24 well hanging drop optimization trays with 500 µl well 
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solution. Components for these solutions were either ordered from Hampton Research 
(usually precipitants for which solvation is difficult) or made in the laboratory and sterile 
filtered with a luer syringe 0.22 micron filter. Once a course optimization was done (ex. 
pH increment 0.5 and ± several percent precipitant on either side of the initial condition) 
from which a condition was chosen, a fine optimization with smaller increments (pH 
increment 0.1 and smaller variations in precipitant) was done to further refine 
conditions. Hanging drops were 1µl complex: 1µl well solution usually, though 2:1 and 
1:2 ratios were tried but did not produce better results. Due to sporadic reproducibility 
and long incubation times for crystals, Hampton Research’s additive screen kit was 
used with one specific optimization condition for both F9 and D3, added according to 
manufacturer’s instructions (10% of well solution) and set up in 96 well trays to 
incubate. This produced marked increases in speed (the D3 condition went from months 
to weeks) and reproducibility of crystal formation, and as previously noted, some of the 
D3 rectangular rods did change to rod clusters, though for the most part, the basic 
crystal morphology did not change with additives, and F9 conditions still contained 
some spherulites.  
Initial (8-9Å) D3 optimized crystals were harvested, cryoprotected, and flash 
frozen in liquid nitrogen. Upon discovery of a large unit cell (~70% water), the 
subsequent batch (6-7Å at best, others same resolution as previous) was harvested, 
and some were treated similarly while others were incubated in a solution containing 
EtOH for 0.5-1 hours before flash freezing in an attempt to decrease water content, the 
efficacy of which is uncertain from diffraction data. The most recent, proliferous batches 
of crystals from the additive screens were harvested in three conditions: glycerol 
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cryoprotectant (0.075 M HEPES pH 7, 28.5% Jeffamine ED-2001, 19% glycerol, 50 mM 
MgCl2, 15 mM glycine, 10% v/v additive), solution with EtOH (0.075 M HEPES pH 7, 
29% Jeffamine ED-2001, 3% glycerol, 50 mM MgCl2, 15 mM glycine, 10% v/v additive, 
15% v/v EtOH) (dehydration inspired by the Group I ribozyme)(128), and solution with 
increased precipitant (0.075 M HEPES pH 7, 38% Jeffamine ED-2001, 50 mM MgCl2, 
15 mM glycine, 10% v/v additive) (dehydration inspired by the glms ribozyme)(129).  
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